Document:

Collaboration & License Agreement

 EXHIBIT 10.1 
  
 CONFIDENTIAL TREATMENT REQUESTED 
  
 CONFIDENTIAL TREATMENT REQUESTED: INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND IS NOTED WITH “[CONFIDENTIAL TREATMENT
REQUESTED].” AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 COLLABORATION AND LICENSE AGREEMENT 
  
 THIS COLLABORATION AND
LICENSE AGREEMENT (the “Agreement”) is made and entered into as of September 3, 2003 (the “Effective Date”), by and between POZEN INC., a Delaware corporation
(“POZEN”), with a business address of 1414 Raleigh Road, Suite 400, Chapel Hill, NC 27517, and XCEL PHARMACEUTICALS, INC., a Delaware corporation (“Xcel”), located
at 6363 Greenwich Drive, Suite 100, San Diego, CA 92122. POZEN and Xcel are sometimes referred to in this Agreement individually as a “Party” and collectively as “Parties.” 
  
 RECITALS 
  
 A. Xcel is a specialty pharmaceutical company focused on the treatment
of disorders of the central nervous system and possesses substantial expertise in the marketing of pharmaceutical products for the treatment of migraine. 
  
 B. POZEN is a pharmaceutical development company currently specializing in the development of products for migraine therapy. 
  
 C. Xcel desires to obtain, and POZEN is willing to grant, the
exclusive right to market, promote, sell and distribute POZEN’s MT 300TM product within the United States of America and its territories in accordance with this Agreement. 
  
 AGREEMENT 
  
 In consideration of the mutual covenants contained in this Agreement and other good and valuable consideration, the receipt and sufficiency of which is
hereby acknowledged, the Parties agree as follows: 
  

	1.	DEFINITIONS 

  
 The capitalized terms used herein will have the meanings given to them in this Section 1 and throughout this Agreement. Unless the context indicates
otherwise, the singular will include the plural and the plural will include the singular. 
  
 1.1 “Affiliate” means a corporation or other business entity which, directly or indirectly, through one or more intermediaries, controls, is controlled by or is under common control with a
Party. For purposes of this definition only, “control” and, with corresponding meanings, the terms “controlled by” and “under common control with,” means (a) the possession, directly or indirectly, of the power to
direct the management or policies of a legal entity, whether through the ownership of voting securities or by contract relating to voting rights 

  

 -1- 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 
or corporate governance, or (b) the ownership, directly or indirectly, of more than 50% of the voting securities or other ownership interest of a legal
entity; provided, however, that if local law restricts foreign ownership, control will be established by direct or indirect ownership of the maximum ownership percentage that may, under such local law, be owned by foreign interests.

  
 1.2 “ANDA” means an abbreviated NDA
filed pursuant to 21 C.F.R. §§ 314.92 et seq. (2003), or any equivalent filing as may be available at the time. 
  
 1.3 “Autoinjector” means the automatic injection device for multiple uses selected by the Parties in accordance with Section
3.2.1. 
  
 1.4 “Autoinjector Presentation”
means the Initial Licensed Product in the Autoinjector. 
  
 1.5
“CMC” has the meaning as set forth in Section 2.1. 
  
 1.6 “Combination Product” means [CONFIDENTIAL TREATMENT REQUESTED]. 
  
 1.7 “Commercial Launch” means nationwide launch of commercial sale, promotion and distribution of a Licensed Product in the
Territory following Marketing Approval for such Licensed Product. 
  
 1.8 “Commercialization” means (a) pre-launch market development activities conducted with a product in anticipation of Marketing Approval, and (b) marketing, promotion, use, advertising, selling, having sold,
distributing or importing a product after Marketing Approval has been obtained. The term “Commercialize” has a correlative meaning. 
  
 1.9 “Commercially Reasonable Efforts” mean, as to either Party relative to any Licensed Product, those efforts and resources
normally used by such Party for a product owned by it which has a similar market potential and is at a similar stage in its product life cycle as the Licensed Product at issue; provided, however, that such efforts and resources will be no
less than those typically applied by a pharmaceutical company of similar size as such Party as of the Effective Date (or any larger size that such Party may have at such later time) for a product owned by such company which has a similar market
potential and is at a similar stage in its product life cycle as the Licensed Product at issue. 
  
 1.10 “Confidential Information” has the meaning as set forth in Section 13.1. 
  
 1.11 “Control” means, with respect to any Patent,
Know-How, Improvement or other intellectual property right, the possession of the ability to grant a license or a sublicense to such Patent, Know-How, Improvement or right as provided for in this Agreement without violating the terms of any
agreement with any Third Party. 
  
 1.12
“Controlled Affiliates” with respect to a Party, mean the Affiliates of such Party which are controlled by such Party (with “controlled by” having the meaning set forth in the definition of “Affiliate”
above). 
  

 2 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 1.13 “Development Costs” mean (a) the direct costs and expenses and (b) the
indirect costs and expenses associated with the operation of any laboratory or manufacturing facilities, in each instance (i) incurred by a Party in carrying out research and development activities agreed to by the Parties and conducted by or on
behalf of a Party as contemplated pursuant to this Agreement and (ii) calculated in accordance with generally accepted accounting principles consistently applied and in accordance with such Party’s cost accounting systems. Development Costs
include all reasonable out-of-pocket costs, such as materials, consultants, and other outside services, attributable to the performance of such activities. Employees of any Party at issue will be charged [CONFIDENTIAL TREATMENT REQUESTED]
(which will be increased once annually on the anniversary of the Effective Date based on any increases of the consumer price index (United States Department of Labor U.S. City Average for All Items, or any successor index) following the Effective
Date). 
  
 1.14 “Development Fees” mean a
Party’s [CONFIDENTIAL TREATMENT REQUESTED]. 
  
 1.15 “Development Study” has the meaning as set forth in Section 3.3.1. 
  
 1.16 “DHE” has the meaning as set forth in Section 4.1.1. 
  
 1.17 “DHE-45” means the injectable formulation of dihydroergotamine described in U.S. NDA
#[CONFIDENTIAL TREATMENT REQUESTED] (as supplemented or amended from time to time). 
  
 1.18 “Dispute Resolution” means the process for resolving Disputes as outlined in Section 16. 
  
 1.19 “Dispute” has the meaning as set forth in Section 16.1. 
  
 1.20 “Excepted Communications” mean information regarding Licensed Products set forth in detail
aids, promotional pieces and sales force reprints of information already in the public domain. 
  
 1.21 “FDA” means the United States Food and Drug Administration, or any successor agency thereof. 
  
 1.22 “FD&C Act” means the United States Federal Food, Drug and Cosmetics Act, as amended from time to time. 
  
 1.23 “Field” means the treatment of [CONFIDENTIAL
TREATMENT REQUESTED] by means of a prescription pharmaceutical product. 
  
 1.24 “First Commercial Sale Date” means the date of the first commercial sale of a Licensed Product by Xcel to a Third Party in the Territory following receipt of Marketing Approval for
such Licensed Product in the Territory. 
  
 1.25
“Foreign Licensed Product” means any Royalty Product which (a) is developed or manufactured inside or outside the Territory for Commercialization outside the Territory or is 

  

 3 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 
Commercialized outside the Territory and (b) would, if developed, manufactured or Commercialized inside the Territory, infringe one or more Valid Claims
under the POZEN Patents; provided, however, that in all events: (i) the Initial Licensed Product and the Autoinjector Presentation are deemed to be Foreign Licensed Products; and (ii) DHE-45 is deemed not to be a Foreign Licensed Product.

  
 1.26 “[CONFIDENTIAL TREATMENT
REQUESTED]” means [CONFIDENTIAL TREATMENT REQUESTED]. 
  
 1.27 “[CONFIDENTIAL TREATMENT REQUESTED]” means [CONFIDENTIAL TREATMENT REQUESTED]. 
  
 1.28 “Improvement” means any invention, discovery or Know-How, whether or not patentable, relating to any Royalty Product and
made, conceived or reduced to practice after the Effective Date and during the Term, but excluding any such invention, discovery or Know-How to the extent incorporated into any Valid Claim within an Xcel Patent or a POZEN Patent. 
  
 1.29 “IND” means an Investigational New Drug
Application filed with the FDA in conformance with applicable laws and regulations. 
  
 1.30 “Initial Licensed Product” means that certain injectable formulation of dihydroergotamine designated by POZEN as MT 300 for which POZEN has filed the POZEN NDA. 
  
 1.31 “Know-How” means non-public information, results
and data of any type whatsoever, in any tangible or intangible form whatsoever, including databases, practices, methods, techniques, specifications, formulations, formulae, knowledge, know-how, skill, experience, test data including pharmacological,
medicinal chemistry, biological, chemical, biochemical, toxicological and clinical test data, analytical and quality control data, stability data, studies and procedures, and manufacturing process and development information, results and data.

  
 1.32 “Knowledge of POZEN” means the
collective knowledge or recollection, as of the Effective Date and as to any facts or circumstances that relate to the subject matter of any representation or warranty at issue, of [CONFIDENTIAL TREATMENT REQUESTED]. 
  
 1.33 “[CONFIDENTIAL TREATMENT REQUESTED]” means
[CONFIDENTIAL TREATMENT REQUESTED]. 
  
 1.34
“[CONFIDENTIAL TREATMENT REQUESTED]” means [CONFIDENTIAL TREATMENT REQUESTED]. 
  
 1.35 “Licensed Product” means any Royalty Product [CONFIDENTIAL TREATMENT REQUESTED]; provided, however, that in all
events: (i) the Initial Licensed Product and the Autoinjector Presentation are deemed to be Licensed Products; and (ii) DHE-45 is deemed not to be a Licensed Product. 
  

 4 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 1.36 “Licensed Technology” means the POZEN Patents, POZEN Know-How and POZEN
Improvements. 
  
 1.37 “Manufacturing Liaison
Costs” mean (a) the direct costs and expenses and (b) the indirect costs and expenses associated with the operation of any laboratory or manufacturing facilities, in each instance (i) incurred by POZEN pursuant to Section 4.4 of this
Agreement in carrying out reasonably necessary manufacturing liaison activities and (ii) calculated in accordance with generally accepted accounting principles consistently applied and in accordance with POZEN’s cost accounting systems.
Manufacturing Liaison Costs include, without limitation, all reasonable out-of-pocket costs, such as materials, consultants, and other outside services, attributable to performance of such activities. Employees of POZEN will be charged
[CONFIDENTIAL TREATMENT REQUESTED] (subject to increase in respect of adjustments to the consumer price index (United States Department of Labor U.S. City Average for All Items, or any successor index) following the Effective Date).

  
 1.38 “Manufacturing Liaison Fee” means
POZEN’s [CONFIDENTIAL TREATMENT REQUESTED]. 
  
 1.39 “Marketing Approval” means the final approval received from the FDA for a product in the United States, immediately following which such product may be commercially sold in the United States. 
  
 1.40 “Marketing Plan” has the meaning as set forth in
Section 5.2.1. 
  
 1.41 “NDA” means a new
drug application submitted to the FDA to obtain FDA approval for the marketing of a pharmaceutical product in the United States. 
  
 1.42 “Net Sales” mean the amount of gross sales of product to Third Parties [CONFIDENTIAL TREATMENT REQUESTED], less the
following deductions: 
  
 (a) Quantity,
trade, cash and other discounts actually allowed or given by Xcel; 
  
 (b) Discounts, replacements, credits, refunds and allowances actually allowed or given by Xcel for product returns or rejections or indigent patient and similar programs; 
  
 (c) Rebates, chargebacks and price adjustments
actually allowed or given by Xcel to customers; 
  
 (d) Actual write-offs of uncollectible amounts receivable by Xcel; provided, however, that if any such amount is in fact subsequently received by Xcel, such received amount will be included in the calculation of Net Sales;

  
 (e) Import, export, excise, sales or
use taxes, value added taxes, and other taxes, tariffs or duties levied, absorbed or directly imposed and properly allocable to product sales (in any event excluding taxes on the income of Xcel); and 
  

 5 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 (f) Freight, postage, shipping, insurance, and packaging costs and other
outbound transportation charges to the extent included in the invoiced amount; 
  
 provided, however, that: 
  
 (x) Net Sales will be determined, without limitation, with reference to the amount or fair market value of all consideration received by Xcel for sale of a product, whether such consideration is in cash,
payment in kind, exchange or other form; provided that if: (i) a product is sold together with other goods, with or without a separate price for such product, (ii) the consideration exchanged for a product includes any non-cash consideration, or
(iii) a product is transferred in any other manner other than as an invoiced sale, then the Net Sales applicable to the quantity of such product included in any such transaction will be deemed to be the average Net Sales for such quantity of such
product for all transactions of such product (other than those described in the preceding clauses (i)-(iii), inclusive) made in the Territory (1) during the last full calendar quarter prior to such transaction, or (2) if there were no Net Sales
during the prior calendar quarter, during the current calendar quarter; 
  
 (y) Products transferred free of charge in connection with the performance of clinical trials, testing, quality control or other development work, or as professional samples will not be included in the
calculation of Net Sales; and 
  
 (z)
Amounts relevant to the determination of Net Sales, and the timing of sales, will be [CONFIDENTIAL TREATMENT REQUESTED]. 
  
 1.43 “Patent” means patents, applications for patents, provisional applications for patents, and any patents issuing therefrom
(including any divisions, continuations, continued prosecution applications and continuations-in-part thereof), reexamination certificates, reissue patents, patent extensions, and patent term restorations. 
  
 1.44 “POZEN Improvements” mean any and all
Improvements owned or Controlled by POZEN that are (a) Technologically Necessary for the development, manufacture or Commercialization of any Licensed Product, or (b) necessary for the development or manufacture of the Initial Licensed Product, or
(c) developed in the course of performing this Agreement solely by POZEN or its Affiliates or Third Party contractors, or jointly by POZEN and Xcel or its or their Affiliates or Third Party contractors, and useful for the development, manufacture or
Commercialization of any Royalty Product. 
  
 1.45
“POZEN Know-How” means any and all Know-How owned or Controlled by POZEN as of the Effective Date that is (a) Technologically Necessary for the development, manufacture or Commercialization of any Licensed Product, or (b)
necessary for the development, manufacture or Commercialization of the Initial Licensed Product, or (c) useful for the development, manufacture or Commercialization of any Royalty Product and is disclosed to Xcel during the Term. 
  
 1.46 “POZEN NDA” means NDA #[CONFIDENTIAL
TREATMENT REQUESTED] (as supplemented or amended from time to time) or any NDA filed as a replacement for such NDA. 
  

 6 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 1.47 “POZEN Patents” mean any and all Patents owned or Controlled by POZEN
during the Term with Valid Claims that would be infringed, in the absence of a license, by the development or Commercialization of any Royalty Product in the Territory, or by the manufacture of any Royalty Product anywhere in the world. In any
event, POZEN Patents include the following: 
  
 (a) those certain patents and patent applications identified on Exhibit D attached hereto; 
  
 (b) any patents that are or may be granted from any of the patents or patent applications referred to in this definition, including
any extensions, continuations, continuations-in-part, divisionals, reissues, reexaminations, renewals, additions, registrations and confirmations thereof; and 
  

(c) any patents or patent applications claiming priority of any of the patents or patent applications referred to in this
definition. 
  
 1.48 “POZEN Trademarks”
mean any trademarks or trade names used or registered by POZEN to identify itself in the Territory. 
  
 1.49 “Product Trademarks” mean any trademarks, trade dress, logos, slogans, and designs, whether or not registered in the
Territory, used to identify or promote any Licensed Product in the Territory, but excluding any Xcel Trademarks or POZEN Trademarks. 
  
 1.50 “Promotional Materials” mean all sales representative training materials and all written, printed, graphic, electronic, audio
or video matter, including but not limited to journal advertisements, sales visual aids, leave-behind items, formulary binders, reprints, direct mail, direct-to-consumer advertising, internet postings, media broadcast advertisements, and sales
reminder aids (for example, note pads, pens and other such items) intended for use or used by Xcel in connection with the promotion of any Licensed Product. 
  
 1.51 “PTO” means the United States Patent and Trademark Office. 
  
 1.52 “Reciprocating Licensee” has the meaning set forth in Section 7.4. 
  
 1.53 “Reference-Listed Drug” means a listed drug
identified by the FDA as a drug product upon which an applicant may rely in seeking approval of an ANDA (or any equivalent process as may be available at the time). 
  
 1.54 “Regulatory Approval” means any approvals and any master files, establishment licenses,
registrations or authorizations of any national or local regulatory agency, department, bureau or other governmental entity, necessary for the manufacture, use, storage, importation, export, transport, distribution or sale of any Licensed Product in
the Field in the Territory. 
  
 1.55 “Royalty
Product” means [CONFIDENTIAL TREATMENT REQUESTED]. 
  
 1.56 “Royalty Term” means the duration of Xcel’s obligation to pay royalties under Section 8.3 as set forth in Section 8.3.2. 
  

 7 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 1.57 “SNDA” means a supplemental NDA filed pursuant to 21 C.F.R. §
314.70 (2003), or any equivalent filing as may be available at the time. 
  
 1.58 “Technologically Necessary” means, with respect to any Improvement or Know-How relative to a Licensed Product, that either (a) such Licensed Product could not be [CONFIDENTIAL TREATMENT
REQUESTED] or (b) the use or development of [CONFIDENTIAL TREATMENT REQUESTED]. 
  
 1.59 “Term” has the meaning as set forth in Section 14.1. 
  
 1.60 “Territory” means the United States of America and its territories (including Puerto Rico). 
  
 1.61 “Third Party” means any individual or entity
other than POZEN, Xcel and their respective Affiliates. 
  
 1.62 “Third Party Payments” mean [CONFIDENTIAL TREATMENT REQUESTED] that are paid by Xcel to any Third Party solely to acquire rights to intellectual property rights that would be infringed or misappropriated
in the absence of a license (a) by the development or Commercialization of the Initial Licensed Product or the Autoinjector Presentation in the Territory, or (b) by the manufacture of the Initial Licensed Product or the Autoinjector Presentation in
any country inside or outside the Territory where any such product is being manufactured (“Blocking IP”). With respect to the Autoinjector Presentation, Blocking IP will not include any intellectual property rights held by the
developer or manufacturer of the Autoinjector to the extent pertaining solely to the Autoinjector. In the event that any payments are made to a Third Party that is not only granting a license to any Blocking IP, but also providing services or
supplying product or materials to Xcel or a Third Party manufacturing the Initial Licensed Product or the Autoinjector Presentation, then the Parties will in good faith determine the applicable amount of such payments made with respect to the
acquisition of rights to Blocking IP, and only such amount will be deemed a Third Party Payment. 
  
 1.63 “Valid Claim” means (a) any claim of an issued and unexpired Patent that has not been held unenforceable or invalid by a
court or other governmental agency of competent jurisdiction in a decision that is not appealed or cannot be appealed, and that has not been disclaimed or admitted to be invalid or unenforceable through reissue, reexamination, disclaimer or
otherwise, and (b) a pending claim in a bona fide, pending patent application so long as such patent claim is prosecuted with customary diligence. Notwithstanding the foregoing clause (b), in the event that a pending claim in a pending patent
application does not issue as a valid and enforceable claim in an issued patent within [CONFIDENTIAL TREATMENT REQUESTED] after the earliest date from which such claim was initially applied for, such a pending claim will not be a Valid Claim,
unless and until such pending claim subsequently issues as a valid and enforceable claim in an issued patent, in which case such claim will be reinstated and be deemed to be a Valid Claim, subject to the other provisions of this definition, as of
the date of issuance of such patent. 
  
 1.64 “Xcel
Improvements” mean any and all Improvements owned or Controlled by Xcel that are (a) Technologically Necessary for the development, manufacture or 

  

 8 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 
Commercialization of any Licensed Product, or (b) necessary for the development or manufacture of the Initial Licensed Product, or (c) developed in the
course of performing this Agreement solely by Xcel or its Affiliates or Third Party contractors, or jointly by Xcel and POZEN or its or their Affiliates or Third Party contractors, and useful for the development, manufacture or Commercialization of
any Royalty Product. 
  
 1.65 “Xcel
Know-How” means any and all Know-How owned or Controlled by Xcel as of the Effective Date that is (a) Technologically Necessary for the development, manufacture or Commercialization of any Licensed Product, or (b) necessary for the
development, manufacture or Commercialization of the Initial Licensed Product, or (c) useful for the development, manufacture or Commercialization of any Royalty Product and is disclosed to POZEN during the Term. 
  
 1.66 “Xcel Patents” mean any and all Patents owned or
Controlled by Xcel during the Term with Valid Claims that would be infringed, in the absence of a license, by the development, manufacture or Commercialization of any Royalty Product. In any event, Xcel Patents include the following: 
  
 (a) those certain patents and patent applications
identified on Exhibit E attached hereto; 
  
 (b) any patents that are or may be granted from any of the patents or patent applications referred to in this definition, including any extensions, continuations, continuations-in-part, divisionals, reissues, reexaminations,
renewals, additions, registrations and confirmations thereof; and 
  
 (c) any patents or patent applications claiming priority of any of the patents or patent applications referred to in this definition. 
  
 1.67 “Xcel Post-Approval Study” means any Xcel-sponsored study funded through a grant to one or more
investigators [CONFIDENTIAL TREATMENT REQUESTED] and conducted with a Licensed Product following Marketing Approval for such Licensed Product. 
  
 1.68 “Xcel Technology” means the Xcel Patents, Xcel Know-How and Xcel Improvements. 
  
 1.69 “Xcel Trademarks” mean any trademarks or trade
names used or registered by Xcel to identify itself in the Territory. 
  

	2.	COLLABORATION GOVERNANCE 

  
 2.1 Formation and Composition of the Collaboration Management Committee. The Parties will manage the Commercialization and further
development of any Licensed Products through a collaboration management committee (the “CMC”). Prior to the first meeting of the CMC, each Party will designate two (2) of its employees as its members on the CMC (although each Party
may bring additional employees to any meeting of the CMC). An alternate member designated by a Party may serve temporarily in the absence of a permanent member. Each Party may replace any of its permanent members of the CMC by providing 

  

 9 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 
written notice thereof to the other Party. Each Party will bear its own costs of participation in the CMC. 
  
 2.2 Functions and Powers of the CMC. The CMC will perform the
following functions, and such other functions assigned to it in this Agreement: [CONFIDENTIAL TREATMENT REQUESTED]. 
  
 2.3 Limitations of CMC Powers. The CMC will have only such powers as are specifically delegated to it in this Agreement, and will have no
power to amend this Agreement or waive a Party’s rights or obligations under this Agreement. 
  
 2.4 CMC Actions. No business will be transacted at any meeting of the CMC unless at least one member from each Party is present. Each Party
will have one vote (i.e., if more than one member attends any meeting of the CMC on behalf of a Party, both members of such Party may collectively exercise only one vote), and actions by the CMC will be taken only with the approval of each
Party. If the CMC is unable to obtain the approval of both Parties on any matter within 15 days of the first vote at which no unanimous decision was reached on such matter, then either Party may refer such matter to the Chief Executive Officers of
the Parties for resolution. If a matter is so referred, then such Chief Executive Officers will meet within 15 days of referral to discuss such matter in good faith. If such discussions do not result in a mutually acceptable resolution within 10
days of such meeting, [CONFIDENTIAL TREATMENT REQUESTED]. Notwithstanding this Section 2.4, either Party may initiate dispute resolution procedures pursuant to Section 16 if the subject of such dispute is alleged to constitute a breach of
contract by the other Party. 
  
 2.5 CMC Meetings.
The CMC will hold meetings at such times and places as will be determined by the Parties, but in no event will such meetings be held in person less frequently than as follows: (a) [CONFIDENTIAL TREATMENT REQUESTED] during the [CONFIDENTIAL
TREATMENT REQUESTED] following the Effective Date; (b) [CONFIDENTIAL TREATMENT REQUESTED] during the [CONFIDENTIAL TREATMENT REQUESTED] following the Effective Date; (c) [CONFIDENTIAL TREATMENT REQUESTED] during
[CONFIDENTIAL TREATMENT REQUESTED] following the Effective Date; and (d) thereafter, [CONFIDENTIAL TREATMENT REQUESTED] upon the request of either Party; provided, however, that any meeting of the CMC which is solely for the
purpose of addressing matters referenced in Section 2.2(d) will not count for purposes of determining whether the provisions of this sentence have been satisfied. The first meeting of the CMC will take place within 90 days after the Effective Date.
In addition to the meetings specified above, if any material matters exist and are pending review or approval by the CMC as contemplated by this Agreement, then either Party may call a meeting of the CMC on at least 30 days’ written notice to
the other Party. 
  

	3.	REGULATORY MATTERS; DEVELOPMENT 

  
 3.1 Initial Licensed Product. 
  
 3.1.1 POZEN has filed the POZEN NDA in its own name and at its own expense. Subject to the provisions of Section 3.4, prior to
approval of the POZEN NDA, 

  

 10 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 
POZEN will be solely responsible for any and all communications with the FDA relating to the Initial Licensed Product or the POZEN NDA. 
  
 3.1.2 Upon approval by the FDA of the POZEN NDA,
POZEN will transfer such approved NDA to Xcel. Following such transfer, Xcel will maintain such NDA during the Term at Xcel’s expense and will (a) obtain and maintain such other Regulatory Approvals as are necessary for the Commercialization of
the Initial Licensed Product in the Territory, and (b) exercise Commercially Reasonable Efforts to cause any manufacturers of the Initial Licensed Product (or any components thereof, as applicable) to obtain and maintain such other Regulatory
Approvals as are necessary for the manufacture at their respective facilities of the Initial Licensed Product (or any components thereof, as applicable) for commercial sale in the Territory. 
  
 3.1.3 POZEN will retain the IND filed by POZEN for
the Initial Licensed Product until POZEN has either (a) [CONFIDENTIAL TREATMENT REQUESTED] the SNDA for the Autoinjector Presentation (the “Autoinjector SNDA”) for submission to the FDA pursuant to Section 3.2 and such SNDA
is approved by the FDA, or (b) [CONFIDENTIAL TREATMENT REQUESTED] the Autoinjector SNDA and Xcel has [CONFIDENTIAL TREATMENT REQUESTED] the Autoinjector SNDA, which ever occurs first. At such time, POZEN will transfer such IND to Xcel,
subject to POZEN’s retained right to have Xcel make filings to such IND on behalf of POZEN, at POZEN’s request and expense, for purposes of further development of Licensed Products by POZEN for use outside the Territory. 
  
 3.1.4 If the FDA requires or suggests that additional
data or information be submitted by POZEN as a condition to approving the POZEN NDA, POZEN will inform Xcel thereof without delay. Subject to Section 3.1.5 below, [CONFIDENTIAL TREATMENT REQUESTED] will conduct such studies (including any
post-approval studies required by the FDA as a condition to approval of the POZEN NDA) as are necessary to satisfy the requests of the FDA, at [CONFIDENTIAL TREATMENT REQUESTED]’s expense. 
  
 3.1.5 Abandonment of POZEN NDA. 
  
 (a) If POZEN determines that the studies necessary
for generating any additional data or information that are required by the FDA for the approval of the POZEN NDA, or that are deemed necessary by POZEN to address issues or respond to questions raised by the FDA, would jeopardize the commercial
viability of the Initial Licensed Product or exceed the financial resources available at POZEN for the Initial Licensed Product, POZEN will inform Xcel thereof without delay. If the Parties are unable to come to a mutually acceptable resolution of
the matter within 30 days, POZEN may elect by written notice to Xcel to withdraw the POZEN NDA and abandon the preparation of an NDA for the Initial Licensed Product; provided, however, that in such event Xcel will be given a reasonable
opportunity (before such withdrawal or abandonment) to assume control of efforts to seek approval of the POZEN NDA at Xcel’s cost (subject to Section 3.1.6 below). If Xcel elects to assume such control, POZEN will (i) exercise its Commercially
Reasonable Efforts (at Xcel’s expense) to assist Xcel with respect to seeking approval of the POZEN NDA, and (ii) transfer the POZEN NDA to Xcel promptly after receipt of such approval. Xcel will provide POZEN with written notice of its 

  

 11 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 
election within 90 days after receiving written notice of POZEN’s intent to withdraw the POZEN NDA and abandon the preparation of an NDA for the Initial
Licensed Product. 
  
 (b) If (i) Xcel does
not assume control of efforts to seek approval of the POZEN NDA as provided in subsection (a) above, or (ii) Xcel assumes such control but terminates its efforts at anytime by written notice to POZEN, or (iii) Xcel assumes such control but does not
undertake or pursue any material development activities during a period of more than [CONFIDENTIAL TREATMENT REQUESTED] (provided that such [CONFIDENTIAL TREATMENT REQUESTED] period will be extended by the period of any delays in such
development activities caused by circumstances outside of Xcel’s reasonable control, but in no event will such extension exceed [CONFIDENTIAL TREATMENT REQUESTED]), this Agreement will terminate upon receipt of the notice by POZEN .

  
 3.1.6 If, pursuant to Section 3.1.5,
POZEN elects to withdraw the POZEN NDA and abandon the preparation of an NDA for the Initial Licensed Product and Xcel assumes control of efforts to seek approval of the POZEN NDA and obtains such approval, then, subject to the terms set forth in
Section 8.4, Xcel may [CONFIDENTIAL TREATMENT REQUESTED] in connection with seeking approval of the POZEN NDA, subject to a limit of [CONFIDENTIAL TREATMENT REQUESTED], against [CONFIDENTIAL TREATMENT REQUESTED] with respect to
the Initial Licensed Product pursuant to Sections 8.2 or 8.3; provided, however, that Xcel may [CONFIDENTIAL TREATMENT REQUESTED] that result from development activities agreed upon by the Parties, with the agreement on the part of
POZEN not to be unreasonably withheld. 
  
 3.2
Autoinjector. 
  
 3.2.1 Within
90 days after the Effective Date, POZEN will prepare the development plan for the Autoinjector Presentation (the “Autoinjector Development Plan”) and will submit such plan for review and approval by the CMC at the next meeting. The
outline of the Autoinjector Development Plan with the target timeline for the submission of the Autoinjector SNDA is attached as Exhibit B. 
  
 3.2.2 POZEN will (a) conduct all development activities relating to the Autoinjector and the Autoinjector Presentation pursuant to
the Autoinjector Development Plan at POZEN’s expense; provided that POZEN will not be required [CONFIDENTIAL TREATMENT REQUESTED] with respect to the performance of the Autoinjector Development Plan; (b) prepare the Autoinjector SNDA at
its own expense, deliver to Xcel such SNDA for filing by Xcel with the FDA and [CONFIDENTIAL TREATMENT REQUESTED]; and (c) subject to the provisions of Section 3.4, be solely responsible for any and all communications with the FDA relating to
the Autoinjector Presentation prior to the filing of the Autoinjector SNDA by Xcel pursuant to Section 3.2.3. 
  
 3.2.3 Xcel will (a) file the Autoinjector SNDA with the FDA, (b) inform POZEN of any material developments with respect to the
Autoinjector Presentation and the Autoinjector SNDA, including any requirements or suggestions by the FDA regarding the submission of data or information as a condition to approving the Autoinjector SNDA; and (c) be the primary point of contact with
the FDA relating to the Autoinjector Presentation and the 

  

 12 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 
Autoinjector SNDA. Upon approval by the FDA of the Autoinjector SNDA, Xcel will maintain the Autoinjector SNDA during the Term at Xcel’s expense and
will (x) obtain and maintain such other Regulatory Approvals as are necessary for the Commercialization of the Autoinjector Presentation in the Territory, and (y) exercise Commercially Reasonable Efforts to cause any manufacturers of the
Autoinjector Presentation (or any components thereof, as applicable) to obtain and maintain such other Regulatory Approvals as are necessary for the manufacture at their respective facilities of the Autoinjector Presentation (or any components
thereof, as applicable) for commercial sale in the Territory. 
  
 3.2.4 If, before or following the initial filing of the Autoinjector SNDA, the FDA requires or suggests or the Parties agree that data or information be submitted as a condition to approving the Autoinjector
SNDA in addition to the data or information that is generated in the performance of the Autoinjector Development Plan, the CMC will discuss how to address such FDA requirements and suggestions and modify the Autoinjector Development Plan as
appropriate. Subject to Section 3.2.5 below, POZEN will perform the modified Autoinjector Development Plan at [CONFIDENTIAL TREATMENT REQUESTED]’s expense. 
  
 3.2.5 If POZEN determines that (a) the performance of the Autoinjector Development Plan would require
[CONFIDENTIAL TREATMENT REQUESTED] in Development Costs, or (b) the studies necessary for generating any additional data or information that are required by the FDA for the approval of the Autoinjector SNDA, or that are deemed necessary by
POZEN or Xcel to address issues or respond to questions raised by the FDA, would jeopardize the commercial viability of the Autoinjector Presentation or exceed [CONFIDENTIAL TREATMENT REQUESTED] in Development Costs, POZEN will inform Xcel
thereof without delay. If the Parties are unable to come to a mutually acceptable resolution of the matter within 30 days, POZEN may elect to abandon the performance of the Autoinjector Development Plan or the preparation of the Autoinjector SNDA;
provided, however, that in such event Xcel will be given a reasonable opportunity (before such abandonment) to assume control of efforts to seek approval of the Autoinjector SNDA at its cost (subject to Section 3.2.6 below). If Xcel elects to
assume such control, POZEN will exercise its Commercially Reasonable Efforts to assist Xcel (at Xcel’s expense) with respect to seeking approval of the Autoinjector SNDA; provided, however, that Xcel may suspend or terminate its efforts
at anytime. 
  
 3.2.6 If, pursuant to
Section 3.2.5, POZEN elects to abandon the development of the Autoinjector Presentation or the preparation of the Autoinjector SNDA and Xcel assumes control of efforts to seek approval of the Autoinjector SNDA and obtains such approval, then,
subject to the terms set forth in Section 8.4, Xcel may [CONFIDENTIAL TREATMENT REQUESTED] in connection with the development of the Autoinjector Presentation or seeking approval of the Autoinjector SNDA, subject to a [CONFIDENTIAL
TREATMENT REQUESTED] plus [CONFIDENTIAL TREATMENT REQUESTED] in Development Costs anticipated in Section 3.2.5 which has not been [CONFIDENTIAL TREATMENT REQUESTED] prior to its abandonment of the development of the Autoinjector
Presentation or the preparation of the Autoinjector SNDA, [CONFIDENTIAL TREATMENT REQUESTED] pursuant to Sections 8.2 or 8.3; provided, however, that Xcel may [CONFIDENTIAL  

  

 13 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 
TREATMENT REQUESTED] result from development activities agreed upon by the Parties, with the agreement on the part of POZEN not to be unreasonably
withheld. 
  
 3.3 Other Licensed Products.

  
 3.3.1 Xcel will have the right, but
not the obligation, to perform development studies with Licensed Products beyond the activities contemplated by Sections 3.1 and 3.2 (each such study, a “Development Study”), including: (a) development of Licensed Products in
injectable formulations and dosage strengths other than those of the Initial Licensed Product; and (b) development of Licensed Products for indications other than the indication for which POZEN has filed the POZEN NDA. Any Development Study
[CONFIDENTIAL TREATMENT REQUESTED], including study designs or protocols for such Development Study, will be subject to review and approval by the CMC. 
  

3.3.2 Xcel will give POZEN written notice of any Xcel Post-Approval Study that is not contemplated by a Marketing Plan
previously reviewed by POZEN prior to initiating such Xcel Post-Approval Study, and POZEN will have the right to review and [CONFIDENTIAL TREATMENT REQUESTED] such Xcel Post-Approval Study. 
  
 3.3.3 If Xcel desires that a Development Study
[CONFIDENTIAL TREATMENT REQUESTED] be conducted, then Xcel will notify POZEN of such desire and will accompany such notice with a description of the objectives for the Development Study. Promptly thereafter, the Parties will prepare a
development plan and budget for such Development Study for review and approval by the CMC (each such plan a “Study Plan”). If POZEN desires to perform such Study Plan, (a) it will notify Xcel in writing prior to the meeting at which
the Study Plan is submitted to the CMC for review and approval and (b) the Parties will negotiate an agreement with customary terms and conditions for the conduct of the Study Plan, including that Xcel will reimburse POZEN monthly on a net 30 days
from invoice date payment basis for POZEN’s Development Fees incurred in connection with such Study Plan. During such time as POZEN holds the IND for the Initial Licensed Product, POZEN agrees to make, on Xcel’s behalf, any required
filings to such IND as may be required for performance of any Study Plan. 
  
 3.3.4 Xcel will, at its own expense, file any NDAs or other regulatory filings for Licensed Products developed in a Development Study under the terms of this Agreement, and upon approval thereof will (a) obtain
and maintain such other Regulatory Approvals as are necessary for the Commercialization of the applicable Licensed Product in the Territory, and (b) exercise Commercially Reasonable Efforts to cause any manufacturers of such Licensed Product (or any
components thereof, as applicable) to obtain and maintain such other Regulatory Approvals as are necessary for the manufacture at their respective facilities of such Licensed Product (or any components thereof, as applicable) for commercial sale in
the Territory. 
  
 3.3.5 POZEN will
provide Xcel with [CONFIDENTIAL TREATMENT REQUESTED] updates on the clinical development programs conducted by or on behalf of POZEN [CONFIDENTIAL TREATMENT REQUESTED] for Foreign Licensed Products (to the extent known to POZEN), where
such activities [CONFIDENTIAL TREATMENT  

  

 14 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 
REQUESTED] the development, manufacture or Commercialization of any Licensed Product in the Field in the Territory. 
  
 3.4 FDA Correspondence. 
  
 3.4.1 To the extent either Party receives any
material written or oral communications relating to any Licensed Product from the FDA, such Party will promptly inform the other Party thereof (including by providing a copy of any such written communication or a written account of any such oral
communication), but in no event later than five business days after receipt of such communication. The Party that is responsible for communicating with the FDA in connection with the development, registration or Commercialization of any Licensed
Product at issue under the terms of this Agreement (i.e., the Party holding the NDA – the “Communicating Party”) will use reasonable efforts to solicit the other Party’s advice and review of the nature and text of
any written communications received from or to be sent to the FDA in reasonably sufficient time prior to responding or dispatching such communications to the FDA, and the Communicating Party will [CONFIDENTIAL TREATMENT REQUESTED] the other
Party’s [CONFIDENTIAL TREATMENT REQUESTED] comments related thereto. 
  
 3.4.2 Each Party will promptly notify the other Party, and provide such other Party with a copy, of any material correspondence or
other reports or complaints submitted to or received by the first Party from the FDA or any Third Party claiming that any Promotional Materials are inconsistent with any Licensed Product labeling or are otherwise in violation of applicable law or
regulation. 
  
 3.4.3 Each Party will
provide the other Party with a copy of any material documents or reports filed with the FDA during the Term with respect to any Licensed Product. 
  
 3.4.4 Prior to the transfer of the POZEN NDA to Xcel from POZEN pursuant to Section 3.1.2, (a) Xcel will be provided with the
opportunity to have an observer in attendance at any in-person meetings or pre-scheduled telephone calls with the FDA with respect to any Licensed Product and (b) the Parties will agree on any change to the labeling for the Initial Licensed Product
(as compared with the draft label included in the POZEN NDA as of the Effective Date). [CONFIDENTIAL TREATMENT REQUESTED]. 
  
 3.5 Adverse Events Reporting. 
  
 3.5.1 For purposes of this Section 3.5: (a) the definition “drug safety reports” shall comply with the requirements set
forth by the FDA in the Code of Federal Regulations, Title 21 CFR 312.32 (“IND Safety Reports”); and (b) all information provided to Xcel pursuant to this Section 3.5 will be provided in a complete and accurate manner. 

 
 3.5.2 During such time as Xcel holds the POZEN NDA
and POZEN holds the IND for the Initial Licensed Product or is performing work under an IND for any Licensed Product or Foreign Licensed Product, POZEN will submit to Xcel all drug safety reports for Licensed Products or Foreign Licensed Products
brought to the attention of POZEN (whether inside or outside the Territory) as well as any material events and matters concerning or affecting 

  

 15 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 
the safety of Licensed Products or Foreign Licensed Products. POZEN will forward copies of all such drug safety reports to Xcel within seven days of receipt
thereof by POZEN. 
  
 3.6 Compliance with Laws.

  
 3.6.1 Xcel will comply with all laws,
regulations, and ordinances (including any laws, regulations, and ordinances prohibiting the promotion of Royalty Products prior to Marketing Approval) applicable to the performance by Xcel of this Agreement (including, as applicable, the
development, manufacture and Commercialization of Royalty Products by Xcel in the Territory). 
  
 3.6.2 POZEN will comply with all laws, regulations, and ordinances applicable to the performance by POZEN of this Agreement.

  
 3.7 Records. Each Party will keep complete,
accurate and authentic accounts, notes, data and records (in good scientific manner and as required by applicable regulatory rules and regulations) of all activities performed by or for it pursuant to this Agreement. 
  

	4.	MANUFACTURE AND SUPPLY 

  
 4.1 Manufacturing and Supply Agreement for [CONFIDENTIAL TREATMENT REQUESTED]. 
  
 4.1.1 Promptly following the Effective Date, Xcel
will exercise good faith efforts to enter into an agreement with [CONFIDENTIAL TREATMENT REQUESTED]. POZEN will exercise good faith efforts to assist Xcel in its discussions and negotiations with [CONFIDENTIAL TREATMENT REQUESTED] with
respect to such agreement. Xcel will keep POZEN informed of the progress of Xcel’s negotiations with [CONFIDENTIAL TREATMENT REQUESTED] and, as applicable, provide POZEN with a near-final draft of such agreement and a copy of such
agreement as executed. 
  
 4.1.2 Xcel
hereby covenants and agrees that, [CONFIDENTIAL TREATMENT REQUESTED]. 
  
 4.2 Manufacturing and Supply Agreement for [CONFIDENTIAL TREATMENT REQUESTED]. 
  
 4.2.1 Promptly following the Effective Date, Xcel will exercise good faith efforts to enter into an agreement with [CONFIDENTIAL
TREATMENT REQUESTED]. POZEN will exercise good faith efforts to assist Xcel in its discussions and negotiations with [CONFIDENTIAL TREATMENT REQUESTED] with respect to such agreement. Xcel will keep POZEN informed of the progress of
Xcel’s negotiations with [CONFIDENTIAL TREATMENT REQUESTED] and, as applicable, provide POZEN with a near-final draft of such agreement and a copy of such agreement as executed. 
  
 4.2.2 The Parties acknowledge that [CONFIDENTIAL
TREATMENT REQUESTED]. POZEN will exercise its Commercially Reasonable Efforts so that, as soon as reasonably possible following the Effective Date, [CONFIDENTIAL TREATMENT  

  

 16 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 
REQUESTED]. [CONFIDENTIAL TREATMENT REQUESTED] will be responsible for [CONFIDENTIAL TREATMENT REQUESTED]. Thereafter, the Parties will
[CONFIDENTIAL TREATMENT REQUESTED], and each of the Parties will exercise its Commercially Reasonable Efforts to [CONFIDENTIAL TREATMENT REQUESTED]. Notwithstanding the preceding sentence, [CONFIDENTIAL TREATMENT REQUESTED].

  
 4.3 Quality Agreement for [CONFIDENTIAL TREATMENT
REQUESTED]. Promptly following the Effective Date, Xcel will exercise good faith efforts to enter into a quality agreement with [CONFIDENTIAL TREATMENT REQUESTED]. POZEN will exercise good faith efforts to assist Xcel in its discussions
and negotiations with [CONFIDENTIAL TREATMENT REQUESTED] with respect to such agreement. Xcel will keep POZEN informed of the progress of Xcel’s negotiations with [CONFIDENTIAL TREATMENT REQUESTED] and, as applicable, provide
POZEN with a near-final draft of such agreement and a copy of such agreement as executed. 
  
 4.4 Supply through POZEN. 
  
 4.4.1 If Xcel is unable to execute an agreement with [CONFIDENTIAL TREATMENT REQUESTED], the Parties will negotiate in good faith regarding an agreement under which POZEN would secure the supply to Xcel
of [CONFIDENTIAL TREATMENT REQUESTED]. The payments to be made by Xcel to POZEN pursuant to subsection (a) and (b) above will be made no later than 10 days in advance of the due date of any payments required to be made by POZEN to
[CONFIDENTIAL TREATMENT REQUESTED]. 
  
 4.4.2 If Xcel is unable to execute an agreement with [CONFIDENTIAL TREATMENT REQUESTED], the Parties will use good faith efforts to secure the supply of [CONFIDENTIAL TREATMENT REQUESTED]. 
  

	5.	COMMERCIALIZATION 

  
 5.1 Principles of Commercialization. 
  
 5.1.1 Xcel will be responsible for the Commercialization of Licensed Products in the Field in the Territory during the Term, and
will use Commercially Reasonable Efforts to perform the activities and apply the resources set forth in each Marketing Plan (defined below) [CONFIDENTIAL TREATMENT REQUESTED]. Except with respect to the costs of the development and regulatory
activities to be performed by POZEN or that may be off-set by Xcel as provided in Sections 3.1 or 3.2, Xcel will bear all expenses incurred in connection with the preparation and execution of each Marketing Plan. 
  
 5.1.2 Promptly after the Effective Date, the
appropriate representatives of each Party will meet to discuss matters pertaining to the manufacture, marketing and promotion of the Initial Licensed Product, including plans for sales force deployment, and the transfer of manufacturing
responsibilities from POZEN to Xcel. Promptly after the Effective Date, the Parties will establish a plan, to be performed at Xcel’s expense, governing the communication of scientific and technical information regarding the Initial Licensed
Product prior to approval of the POZEN NDA, including any such information to be included in papers, posters, conference presentations, focus group activities, conferences and meetings with doctors, and Xcel will 

  

 17 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 
adhere to such plan in its communications with Third Parties prior to approval of the POZEN NDA; provided, however, that the following activities will
not be subject to such plan or the restrictions of this sentence: advisory board meetings, market research activities and the development of marketing campaigns or sales and marketing materials for use after approval of the POZEN NDA (as well as any
activities reasonably related to such activities). 
  
 5.2
Marketing Plan. 
  
 5.2.1 Xcel
will prepare a marketing plan for the Licensed Products for 2004 (the “Marketing Plan”) and provide a copy of the Marketing Plan to POZEN for comment [CONFIDENTIAL TREATMENT REQUESTED]. POZEN will provide its comments to the
Marketing Plan to Xcel [CONFIDENTIAL TREATMENT REQUESTED], and Xcel will finalize the Marketing Plan [CONFIDENTIAL TREATMENT REQUESTED]. The outline of the initial Marketing Plan for the Initial Licensed Products is attached hereto as
Exhibit C. 
  
 5.2.2 Xcel will
update the Marketing Plan at least once every year, and will submit each updated Marketing Plan to POZEN for review and comment in accordance with Xcel’s corporate planning cycle and with sufficient lead time for POZEN to have a reasonable
opportunity to review and comment on such updated Marketing Plan. 
  
 5.2.3 Each Marketing Plan will include, [CONFIDENTIAL TREATMENT REQUESTED]. 
  
 5.3 Co-Promotion. 
  
 5.3.1 POZEN may co-promote any Licensed Product in the Territory in the event that: 
  
 (a) [CONFIDENTIAL TREATMENT REQUESTED]; or

  
 (b) [CONFIDENTIAL TREATMENT
REQUESTED]. 
  
 5.3.2 If Section
5.3.1(b) above is applicable, then, for a period of 60 days thereafter, the Parties will negotiate in good faith a co-promotion agreement governing the co-promotion of the applicable Licensed Product by POZEN in the Territory (with the intent that
such agreement will contain terms and conditions customary for a co-promotion agreement in the pharmaceutical industry, as well as providing for a co-promotion role for POZEN in the marketing and promotion of the applicable Licensed Product
commensurate with [CONFIDENTIAL TREATMENT REQUESTED] and in accordance with the Marketing Plan then in effect, although Xcel will set the sales price, [CONFIDENTIAL TREATMENT REQUESTED], and book all sales revenue). If the Parties are
unable to agree on all terms of such a co-promotion agreement with respect to the applicable Licensed Product prior to expiration of such 60-day period, then either Party may invoke and proceed in accordance with the dispute resolution procedure set
forth in Exhibit F attached hereto. 
  
 5.3.3 If Xcel desires to enter into a co-promotion arrangement for a Licensed Product with a Third Party, subject to the terms set forth in Section 5.3.4 below, then Xcel will notify POZEN of such desire and will accompany such
notice with a description of the intended 

  

 18 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 
role for such Third Party (including a description of related requirements such as the number and territory of sales representatives and the number,
frequency and positioning of details). If POZEN desires to perform such co-promotion arrangement, it will notify Xcel in writing within 30 days after receipt of the corresponding notice from Xcel. In the event that POZEN is able to provide the
resources that Xcel is seeking for the performance of the requirements identified by Xcel, promptly thereafter the Parties will negotiate, for a period of 60 days, a co-promotion agreement governing the co-promotion of the applicable Licensed
Product by POZEN in the Territory (with the intent that such agreement will provide for a co-promotion role for POZEN in the marketing and promotion of the applicable Licensed Product corresponding to the role for any Third Party described by Xcel
in its notice to POZEN (and in accordance with the Marketing Plan then in effect), although Xcel will set the sales price, [CONFIDENTIAL TREATMENT REQUESTED], and book all sales revenue). If the Parties are not able to agree upon such a
co-promotion agreement within such 60-day period, then Xcel may seek to have a Third Party perform the co-promotion arrangement; provided, however, that Xcel may not offer to any such Third Party terms which are, in the aggregate, more
beneficial to such Third Party than the last offer made by Xcel to POZEN during the above-referenced 60-day negotiating period without providing POZEN with a period of at least 10 days to accept any improved terms which Xcel intends to offer to any
Third Party. 
  
 5.3.4 Notwithstanding
anything in this Agreement to the contrary, (a) Xcel may enter into a co-promotion arrangement with a Third Party for Licensed Products only if such arrangement: [CONFIDENTIAL TREATMENT REQUESTED], and (b) subject to the limitations set forth
in subsection (a) above, Xcel is not required to first offer co-promotion rights to POZEN pursuant to Section 5.3.3 with respect to a proposed co-promotion arrangement with a Third Party pursuant to which [CONFIDENTIAL TREATMENT REQUESTED].

  
 5.4 Branding; Trademarks; Trade Dress; Logos.

  
 5.4.1 Following the Effective Date,
the Parties will work together to select a Product Trademark for the Initial Licensed Product. In the event that the Parties have not agreed upon such a Product Trademark by October 30, 2003, then [CONFIDENTIAL TREATMENT REQUESTED] may select
a Product Trademark for the Initial Licensed Product, subject to the approval of [CONFIDENTIAL TREATMENT REQUESTED]. Xcel will thereafter use such Product Trademark in the Commercialization of the Initial Licensed Product. 
  
 5.4.2 Prior to Marketing Approval for any Licensed
Product other than the Initial Licensed Product, the Parties will work together to determine a Product Trademark for such Licensed Product. In the event that the Parties have not agreed upon such a Product Trademark within 60 days of Xcel’s
delivery to POZEN of notice that a Product Trademark is required for such Licensed Product in order for Xcel properly to commence pre-launch market development activities in anticipation of Marketing Approval for such Licensed Product, then
[CONFIDENTIAL TREATMENT REQUESTED] may select a Product Trademark for the Licensed Product, subject to the approval of [CONFIDENTIAL TREATMENT REQUESTED]. Xcel will thereafter use such Product Trademark in the Commercialization of such
Licensed Product.  
  

 19 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 5.4.3 At the request of POZEN, Xcel will, to the extent permitted by law
(including applicable FDA regulations), include any POZEN Trademark designated by POZEN (the “Designated POZEN Trademark”) on any joint press releases and seminar and conference posters and presentations regarding any Licensed
Product. Prior to any such use, Xcel will provide POZEN with an opportunity to review and comment upon the planned use of the Designated POZEN Trademark. In addition, any such use of the Designated POZEN Trademark will comply with the provisions of
Section 5.4.5. 
  
 5.4.4 POZEN will be the
sole owner of the Product Trademarks. In consideration for the licenses granted by POZEN to Xcel for Product Trademarks under this Agreement, Xcel will pay to POZEN a royalty of [CONFIDENTIAL TREATMENT REQUESTED] for the duration of the use
of any such Product Trademarks by Xcel [CONFIDENTIAL TREATMENT REQUESTED]. 
  
 5.4.5 In connection with the use of any Product Trademarks or any Designated POZEN Trademark, Xcel will (a) place the appropriate
trademark symbol, such as TM or ®, adjacent to any
Product Trademark or Designated POZEN Trademark and (b) not use such Product Trademark or Designated POZEN Trademark as an adjective or in the plural or possessive form. Xcel recognizes and agrees that such steps are necessary to protect and enhance
the value and goodwill of the Product Trademarks or any Designated POZEN Trademark. POZEN will have the right to review any Product Promotional Materials and any labels or packaging materials prepared by or for Xcel that bear any Product Trademarks
or any Designated POZEN Trademark in order to confirm that such trademarks are being used in all material respects in accordance with the terms of this Section 5.4.5. Upon written notice of non-compliance from POZEN to Xcel, Xcel will modify the
applicable Product Promotional Materials, labels, or packaging materials to make them comply with the terms of this Section 5.4.5. 
  
 5.4.6 POZEN reserves all rights in the Product Trademarks and the POZEN Trademarks not expressly granted to Xcel in this Agreement.
Xcel acknowledges POZEN’s exclusive right, title and interest in and to the Product Trademarks and POZEN Trademarks and acknowledges that nothing herein will be construed to accord to Xcel any rights in such trademarks except as expressly
provided herein. Xcel further acknowledges that its use of the Product Trademarks and POZEN Trademarks will not create in Xcel any right, title or interest in such trademarks, and that all use of such trademarks and the goodwill generated thereby
will inure solely to the benefit of POZEN. Upon any termination of this Agreement, Xcel hereby agrees not to [CONFIDENTIAL TREATMENT REQUESTED]. 
  
 5.4.7 Except as expressly permitted herein, POZEN will not use, or knowingly permit any Third Party to use, any Product Trademarks
except in connection with the development, manufacture and Commercialization outside of the Territory of Foreign Licensed Products, and will impose on all direct or indirect licensees of Foreign Licensed Products using the Product Trademarks
obligations similar to those imposed on Xcel pursuant to Section 5.4.5. 
  

 20 

 CONFIDENTIAL TREATMENT REQUESTED 
  

	6.	DILIGENCE 

  
 6.1 General Diligence Obligations. Xcel will, during the Term, exercise Commercially Reasonable Efforts to Commercialize the Licensed
Products in the Field in the Territory following receipt of Marketing Approval. 
  
 6.2 Minimum Launch Diligence Obligations. Without limiting the diligence obligations of Section 6.1 above, Xcel will conduct the Commercial Launch of each Licensed Product in the Territory as soon as
reasonably possible after receipt of Marketing Approval for such Licensed Product, but in no event later than [CONFIDENTIAL TREATMENT REQUESTED]. Without limiting the diligence obligations of Section 6.1 above, Xcel will conduct the
Commercial Launch of the Initial Licensed Product in the Territory before conducting the Commercial Launch of any other Licensed Product in the Territory. 
  
 6.3 Minimum Commercialization Diligence Obligations. Without limiting the diligence obligations of Section 6.1 above, during the
[CONFIDENTIAL TREATMENT REQUESTED] following the First Commercial Sale Date for the Initial Licensed Product, Xcel will: [CONFIDENTIAL TREATMENT REQUESTED]. 
  
 6.4 Lack of Diligence. Any material failure by Xcel to fulfill a diligence obligation set forth in this
Section 6 will be deemed a material breach of this Agreement. Xcel’s fulfillment of the diligence obligations set forth in Sections 6.2 and 6.3 will be taken into account when determining whether Xcel has fulfilled its obligations set forth in
Section 6.1, but will not be considered conclusive proof that such obligations have also been fulfilled. 
  

	7.	LICENSES AND OTHER RIGHTS 

  
 7.1 Grants to Xcel. Subject to the terms and conditions set forth in this Agreement, POZEN hereby grants to Xcel: 
  
 7.1.1 An exclusive license (even as to POZEN) under
the Licensed Technology to Commercialize Royalty Products in the Field in the Territory; 
  
 7.1.2 Except as provided in Section 4.1.2, a worldwide, non-exclusive license under the Licensed Technology to make or have made
Royalty Products for Commercialization in the Field in the Territory; 
  
 7.1.3 A non-exclusive license under the Licensed Technology to develop Royalty Products in the Territory; 
  
  
  
 7.1.4 An exclusive license (even as to POZEN) to use the Product Trademarks in connection with the Commercialization of Licensed Products in the Territory; and 
  
 7.1.5 A non-exclusive license to use Designated POZEN
Trademarks pursuant to Section 5.4.3. 
  
 7.2
Sublicenses by Xcel. Except for any co-promotion arrangements entered into by Xcel with any Third Parties in accordance with Section 5.3, the licenses granted in Sections 

  

 21 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 
7.1.1, 7.1.4 and 7.1.5 are not sublicensable by Xcel. The licenses granted to Xcel in Section 7.1 in connection with any co-promotion arrangement entered
into in accordance with Section 5.3, and the licenses granted to Xcel in Section in 7.1.2 and 7.1.3, are sublicensable by Xcel. Xcel will impose on any sublicensee of Xcel’s rights such obligations as may be necessary for (a) Xcel to be able to
perform its obligations under this Agreement and (b) the required performance of such sublicensee to be in compliance with the requirements of this Agreement. 
  

7.3 Grants to POZEN. Subject to the terms and conditions set forth in this Agreement, Xcel hereby grants to POZEN: 
  
 7.3.1 An exclusive license (even as to Xcel) under
the Xcel Technology, but solely to Commercialize in the Field outside the Territory any Foreign Licensed Products; 
  
 7.3.2 A non-exclusive, worldwide license under the Xcel Technology, but solely to develop, make or have made for Commercialization
in the Field outside the Territory any Foreign Licensed Products; and 
  
 7.3.3 The non-exclusive right to use and reference the filed or approved POZEN NDA and the Autoinjector SNDA (and, if applicable, the NDA for any Licensed Product other than the Initial Licensed Product) and
any data and information contained in such filed or approved POZEN NDA or Autoinjector SNDA (or, if applicable, such other NDA) for (a) the development, registration and Commercialization of products other than Royalty Products inside the Territory,
(b) the development of Foreign Licensed Products inside or outside the Territory, and (c) the registration and Commercialization of Foreign Licensed Products outside the Territory. 
  
 7.4 Sublicenses by POZEN. The licenses and rights granted in Section 7.3 are sublicensable by POZEN without
the prior written consent of Xcel, but only if the following conditions are met: (a) any sublicensee is, with respect to any territory at issue, concurrently receiving from POZEN a license under one or more Patents Controlled by POZEN to
Commercialize Foreign Licensed Products in the Field in such territory; (b) such license is granted with the same scope of exclusivity and under the same termination and expiration terms as the sublicenses granted under the licenses and rights
granted in Section 7.3; (c) such sublicensee is licensing to POZEN [CONFIDENTIAL TREATMENT REQUESTED] owned or Controlled by such sublicensee that are [CONFIDENTIAL TREATMENT REQUESTED] for the development, manufacture, having
manufactured or Commercialization of any Licensed Products in the Field in the Territory, which license to POZEN is to be sublicensable (and deemed sublicensed) to Xcel in accordance with the terms of the licenses granted in Section 7.1; and (d)
Xcel receives prior written notice of any such sublicense. Any sublicensee in an arrangement meeting the requirements of the foregoing clauses (a), (b), (c) and (d) is herein referred to as a “Reciprocating Licensee.”
Notwithstanding the foregoing, POZEN will have the right to sublicense to any of its licensees its right of use and reference of the filed or approved POZEN NDA and the Autoinjector SNDA and any data and information contained in such filed or
approved POZEN NDA or Autoinjector SNDA for (a) the development, registration and Commercialization of products other than Royalty Products inside the Territory, (b) the development of Foreign Licensed Products inside and outside the Territory and
(c) the registration and Commercialization of Foreign Licensed Products outside the Territory. 
  

 22 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 7.5 Negative Covenants. 
  
 7.5.1 Xcel covenants and agrees that it will not (a) use or practice the Licensed Technology or the
Product Trademarks, except as expressly permitted by this Agreement, (b) use or practice the Licensed Technology for the purposes of developing, distributing or Commercializing any Licensed Product for non-prescription sale, (c) apply for any
Regulatory Approval that would allow the over-the-counter sale of any Licensed Product, (d) sell any Licensed Product to patients without a prescription therefore, (e) sell, or knowingly permit any Third Party to sell, any Licensed Product for
export, distribution, resale or use outside the Territory or (f) [CONFIDENTIAL TREATMENT REQUESTED]. 
  
 7.5.2 POZEN covenants and agrees that it will not (a) use or practice the Xcel Technology, except as expressly permitted by this
Agreement, (b) sell, or knowingly permit any Third Party to sell, any Royalty Product for import, distribution, resale or use in the Territory, (c) conduct any Commercialization, or knowingly permit any Third Party to conduct any Commercialization,
of any Royalty Product in the Territory, (d) [CONFIDENTIAL TREATMENT REQUESTED], or, (e) except for Third Parties which are obligated to POZEN to maintain confidentiality of the same in accordance with arrangements which are at least as
protective as the provisions set forth in Section 13 or as expressly contemplated by this Agreement, disclose any Licensed Technology, or any Confidential Information of POZEN relating to any Licensed Technology, to any Third Party. 
  
 7.5.3 [CONFIDENTIAL TREATMENT REQUESTED].

  
 7.5.4 [CONFIDENTIAL TREATMENT
REQUESTED]. 
  
 7.5.5 Except for the
rights specifically granted in this Agreement, each Party expressly reserves (a) all rights owned or controlled by it, including as to all products and intellectual property rights, and (b) the right to utilize, and to allow Third Parties to
utilize, such products and intellectual property rights in any manner not inconsistent with the terms of this Agreement. 
  
 7.6 Upstream Licensors of Future Technology. 
  
 7.6.1 With respect to any intellectual property rights included in any POZEN Improvement or POZEN Patent acquired by or licensed to
POZEN from a Third Party after the Effective Date and practiced by Xcel in the development, manufacture or Commercialization of any Royalty Product other than the Initial Licensed Product as envisaged as of the Effective Date, such intellectual
property rights will not be included in the licenses granted under Section 7.1 unless Xcel agrees to pay to POZEN any amounts that may become due to any such Third Party licensor as a result of the practice of such intellectual property rights by
Xcel pursuant to the licenses granted under Section 7.1, with such payment to be made no later than 10 days prior to the date POZEN’s payment is due to such Third Party licensor. POZEN will provide written notice to Xcel describing any payment
obligations associated with the practice of any such intellectual property rights at the time POZEN discloses such intellectual property rights or related information or technology to Xcel. 
  

 23 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 7.6.2 With respect to any intellectual property rights included in any Xcel
Improvement or Xcel Patent acquired by or licensed to Xcel from a Third Party after the Effective Date and practiced by POZEN or any Reciprocating Licensee in the development, manufacture or Commercialization of any Licensed Product or Foreign
Licensed Product other than the Initial Licensed Product as envisaged as of the Effective Date, such intellectual property rights will not be included in the licenses granted under Section 7.3 unless POZEN agrees to pay to Xcel any amounts that may
become due to any such Third Party licensor as a result of the practice of such intellectual property rights by POZEN or any such Reciprocating Licensee pursuant to the licenses granted under Section 7.3, with such payment to be made no later than
10 days prior to the date Xcel’s payment is due to such Third Party licensor. Xcel will provide written notice to POZEN describing any payment obligations associated with the practice of any such intellectual property rights at the time Xcel
discloses such intellectual property rights or related information or technology to POZEN. 
  

	8.	COMPENSATION 

  
 8.1 License Fees. Xcel will pay to POZEN a non-refundable, non-creditable license fee of US$2,000,000 on the Effective Date. 
  
 8.2 Milestones. Subject to the terms and conditions of this
Agreement, Xcel will make the following non-refundable, non-creditable payments to POZEN in the amounts set forth below within 15 days of the occurrence of the related event: 
  

	 Milestone Event

	  	Milestone Payment

	 (1) [CONFIDENTIAL TREATMENT REQUESTED]
	  	[CONFIDENTIAL TREATMENT REQUESTED]
	 (2) [CONFIDENTIAL TREATMENT REQUESTED]
	  	[CONFIDENTIAL TREATMENT REQUESTED]
	 (3) [CONFIDENTIAL TREATMENT REQUESTED]
	  	[CONFIDENTIAL TREATMENT REQUESTED]

  
 8.3
Royalties. 
  
 8.3.1 Royalty
Rate. Subject to the terms and conditions of this Agreement, Xcel will pay to POZEN a royalty, based on aggregate Net Sales of Royalty Products in the Territory for each calendar year during the Royalty Term, as follows: [CONFIDENTIAL
TREATMENT REQUESTED]. 
  
 8.3.2
Royalty Term. Royalties due under this Section 8.3 will be payable with respect to all Royalty Products for the period (the “Royalty Term”) commencing on the First 

  

 24 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 
Commercial Sale Date of the first Licensed Product and ending on [CONFIDENTIAL TREATMENT REQUESTED]. 
  
 8.4 Offsets. 
  
 8.4.1 Subject to the terms of this Section 8.4, Xcel
may offset up to [CONFIDENTIAL TREATMENT REQUESTED] of any Third Party Payments against any of the payments required to be made by Xcel in Section 8.2, or any of the payments made by Xcel in Section 8.3 based on Net Sales of the Initial
Licensed Product, the Autoinjector Presentation or DHE-45. 
  
 8.4.2 Notwithstanding any provision herein to the contrary, the amount of any offsets taken by Xcel pursuant to Sections 3.1.6, 3.2.6, and 8.4.1, in the aggregate, will be subject to a maximum, as to any
specific payment, of [CONFIDENTIAL TREATMENT REQUESTED] of the amount payable by Xcel under this Agreement prior to application of the offset(s), although any amounts not offset with respect to any specific payment may be carried forward for
offset against any other payment. 
  
 8.4.3
Notwithstanding any provision herein to the contrary, Xcel will not be entitled to take any offset pursuant to Sections 3.1.6, 3.2.6, or 8.4.1 from royalties due for Net Sales of a Licensed Product during such time as [CONFIDENTIAL TREATMENT
REQUESTED]. 
  
 8.5 [CONFIDENTIAL TREATMENT
REQUESTED]. [CONFIDENTIAL TREATMENT REQUESTED] will be calculated on a calendar quarterly basis. [CONFIDENTIAL TREATMENT REQUESTED], as documented by Xcel pursuant to this Section 8.5. Xcel will notify POZEN in writing promptly
upon its determination that [CONFIDENTIAL TREATMENT REQUESTED] with respect to a calendar quarter and will provide with such notice such information and documentation as is reasonably necessary for POZEN to confirm the accuracy of such
determination. 
  
 8.6 Payments and Reports.
Payments required to be made by Xcel in Section 8.3 will be made on a calendar quarter basis (calculated as the amount owed for the then current calendar year through the end of such quarter less any amounts previously paid in respect of such year),
with such payments to be (a) made within [CONFIDENTIAL TREATMENT REQUESTED] after the end of the applicable calendar quarter and (b) accompanied by a written report setting forth in reasonable detail the calculation of the amount of the
payment made; provided, however, that (i) within [CONFIDENTIAL TREATMENT REQUESTED] of the end of each calendar quarter, Xcel will provide POZEN with a report stating the number of units of each Royalty Product sold by Xcel during the
relevant payment period, the amount of gross sales, any deductions taken in the calculation of Net Sales, and the royalty payable pursuant to Section 8.3 in respect of such quarter, and (ii) if any information bearing on the amount of any royalty
payment pursuant to Section 8.3 [CONFIDENTIAL TREATMENT REQUESTED] becomes known following the making of any such payment (or the delivery of any related report), adjustments will be made in subsequent payments (i.e., to
“true-up” the aggregate amount of royalty payments made) and the reports made with respect to such subsequent payments will indicate the basis and amount of any such adjustments. 
  

 25 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 8.7 Payment Method; Currency. Xcel will make all payments under this Agreement in
United States dollars by wire transfer in immediately available funds to an account designated by POZEN. Any payments or portions thereof due hereunder that are not paid on the date such payments are due under this Agreement will bear interest at a
per annum rate equal to the lesser of (a) the prime rate as published in The Wall Street Journal, Eastern Edition, on the first day of each calendar quarter in which such payments are overdue, [CONFIDENTIAL TREATMENT REQUESTED], and (b) the
maximum rate permitted by law, calculated on the number of days such payment is delinquent. 
  
 8.8 Taxes. Xcel will have the right to withhold taxes in the event that authorities in the Territory require the withholding of taxes on amounts paid hereunder to POZEN. Such taxes will be deducted by
Xcel from such payment and will be paid by Xcel to the proper taxing authority on behalf of POZEN. Xcel will promptly secure and send to POZEN proof evidencing payment of such taxes withheld and paid by Xcel for the benefit of POZEN. Xcel will
assist POZEN in claiming exemption from such deductions or withholdings under any applicable tax treaty by providing such documentation as may be reasonably required by POZEN to claim such exemption. 
  
 8.9 Audit Rights; Adjustments. 
  
 8.9.1 Each Party (the “Audited
Party”) will permit an independent certified public accountant designated by the other Party (the “Auditing Party”) and reasonably acceptable to the Audited Party (the “Auditor”) to have access to the
Audited Party’s records and books, insofar as the same relate to any of the payments to be made under the provisions of this Agreement, for the sole purpose of determining the accuracy of the amounts reported and actually paid or otherwise
payable under the terms of this Agreement (the “Audit”); provided, however, that (i) any Audit will cover a period not to exceed three years immediately preceding such Audit, (ii) each period may be the subject of only one Audit,
(iii) the Auditor will agree to (x) execute and be bound by a confidentiality agreement in customary form and (y) reveal only the results of the Audit (the “Auditor’s Results”) to the Auditing Party (and not, for example, the
information reviewed with respect thereto), (iv) the Auditing Party will bear all costs and expenses in connection with any Audit, (v) any Audit will be performed during a mutually determined period upon at least 30 calendar days’ prior written
notice during regular business hours, and (vi) Audits will not be requested by any one Party to occur more than once in each calendar year during the Term and once following expiration or termination of this Agreement. 
  
 8.9.2 Where the Audit relates to royalty payments
made by Xcel under Section 8.3: (a) if the Auditor’s Results determine that any royalty payment(s) at issue have been overstated, then POZEN will repay to the Xcel the amount of any resulting overpayment within 30 days after receipt of the
Auditor’s Results, after deducting the reasonable costs and expenses incurred by POZEN in connection with the Audit; and (b) if the Auditor’s Results determine that any royalty payment(s) at issue have been understated, then (i) Xcel will
pay to POZEN the amount of any resulting underpayment within 30 days after receipt of the Auditor’s Results together with interest on any underpayment from the date originally due, calculated at a per annum rate equal to the prime rate as
published in The Wall Street Journal, Eastern Edition, on the first day of each calendar quarter in which such underpayment occurs, [CONFIDENTIAL TREATMENT REQUESTED], and, (ii) where the underpayment of any royalty payment(s) at 

  

 26 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 
issue is greater than [CONFIDENTIAL TREATMENT REQUESTED] of the amount of such royalty payment(s) actually due under the terms of this Agreement, then
Xcel will reimburse POZEN for the reasonable costs and expenses incurred by POZEN in connection with the Audit. 
  
 8.9.3 Where the Audit relates to payments made by Xcel to POZEN other than royalty payments under Section 8.3 (e.g., payments for
Development Fees pursuant to a Study Plan as contemplated by Section 3.3.3 or payments for Manufacturing Liaison Fees as contemplated by Section 4.4): (a) if the Auditor’s Results determine that any payment(s) at issue have been overstated,
then (i) POZEN will repay to Xcel the amount of any resulting overpayment within 30 days after receipt of the Auditor’s Results together with interest on any overpayment from the date originally due, calculated at a per annum rate equal to the
prime rate as published in The Wall Street Journal, Eastern Edition, on the first day of each calendar quarter in which such overpayment occurs, [CONFIDENTIAL TREATMENT REQUESTED], and, (ii) where the overpayment of any payment(s) at issue is
greater than [CONFIDENTIAL TREATMENT REQUESTED] of the amount of such payment(s) actually due under the terms of this Agreement, then POZEN will reimburse Xcel for the reasonable costs and expenses incurred by Xcel in connection with the
Audit; and (b) if the Auditor’s Results determine that any underpayment has occurred, then Xcel will pay to POZEN the amount of any resulting underpayment within 30 days after receipt of the Auditor’s Results, after deducting the
reasonable costs and expenses incurred by Xcel in connection with the Audit. 
  
 8.9.4 In connection with any audits of POZEN’s books and records conducted on behalf of [CONFIDENTIAL TREATMENT REQUESTED] or its Affiliates pursuant to the [CONFIDENTIAL TREATMENT
REQUESTED], POZEN will have the right to make available to [CONFIDENTIAL TREATMENT REQUESTED] and its Affiliates any Auditor’s Results with respect to Xcel’s books and records insofar as the same address matters affecting
[CONFIDENTIAL TREATMENT REQUESTED] under [CONFIDENTIAL TREATMENT REQUESTED].  
  

	9.	INTELLECTUAL PROPERTY 

  
 9.1 Ownership. All right, title and interest in and to the Licensed Technology, POZEN Trademarks, and Product Trademarks
will remain exclusively with POZEN, subject only to the licenses granted to Xcel under this Agreement. All right, title and interest in and to the Xcel Technology will remain exclusively with Xcel, subject only to the licenses granted to POZEN under
this Agreement. 
  
 9.2 Patent and Trademark Filing,
Prosecution and Maintenance. 
  
 9.2.1
As between the Parties, POZEN will have the first right, using counsel of its choice, to prepare, file, prosecute, maintain and obtain extensions of all POZEN Patents and Product Trademarks in the Territory, subject to any obligations POZEN may
have to Third Parties with respect to POZEN Patents that are licensed by such Third Party to POZEN. If POZEN undertakes any such activities, then (a) POZEN will bear the costs relating to such activities, (b) POZEN will consider in good faith the
interests of Xcel in so doing and (c) POZEN will use Commercially Reasonable Efforts to obtain the strongest commercially reasonable patent or trademark protection (under the circumstances and, as to patent protection, 

  

 27 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 
for applications of each POZEN Patent for Royalty Products). POZEN will use reasonable efforts to solicit Xcel’s advice and review of the nature and
text of POZEN Patents, applications for Product Trademarks and material prosecution matters related thereto in reasonably sufficient time prior to filing thereof or action thereon, and POZEN will consider in good faith Xcel’s reasonable
comments related thereto. 
  
 9.2.2 If
POZEN, prior or subsequent to filing any POZEN Patent owned by POZEN or any application for a Product Trademark, elects not to file, prosecute or maintain such POZEN Patent or such application for a Product Trademark, then POZEN will give Xcel
written notice thereof within a reasonable period prior to allowing such POZEN Patent or such application to lapse or become abandoned or unenforceable, and Xcel will thereafter have the right, at its expense, to assume title and ownership to, and
to prepare, file, prosecute and maintain, such POZEN Patent or such application for a Product Trademark. 
  
 9.2.3 As between the Parties, Xcel will have the first right, using counsel of its choice, to prepare, file, prosecute, maintain
and obtain extensions of all Xcel Patents, subject to any obligations Xcel may have to Third Parties with respect to Xcel Patents that are licensed by such Third Party to Xcel. If Xcel undertakes any such activities, then (i) Xcel will bear the
costs relating to such activities, (ii) Xcel will consider in good faith, to the extent that any such Xcel Patent relates to any Licensed Product, the interests of POZEN in so doing and (iii) Xcel will use Commercially Reasonable Efforts to obtain
the strongest commercially reasonable patent or trademark protection (under the circumstances and, as to patent protection to the extent that any such Xcel Patent relates to any Licensed Product, for applications of such Xcel Patent for Licensed
Products). To the extent that any such Xcel Patent relates to any Licensed Product, Xcel will use reasonable efforts to solicit POZEN’s advice and review of the nature and text of such Xcel Patent and material prosecution matters related
thereto in reasonably sufficient time prior to filing thereof or action thereon, and Xcel will consider in good faith POZEN’s reasonable comments related thereto. 
  
 9.2.4 If Xcel, prior or subsequent to filing any Xcel Patent owned by Xcel, elects not to file,
prosecute or maintain such Xcel Patent, then Xcel will give POZEN written notice thereof within a reasonable period prior to allowing such Xcel Patent to lapse or become abandoned or unenforceable, and POZEN will thereafter have the right, at its
expense, to assume title and ownership to, and to prepare, file, prosecute and maintain, such Xcel Patent. 
  
 9.3 Improvements. 
  
 9.3.1 All Improvements made jointly by employees of POZEN and Xcel (or their Affiliates or Third Party contractors), and all joint
Know-How, will be owned jointly by the Parties and each Party will retain full ownership under any Patents resulting therefrom, with full ownership rights in any field and, subject to the licenses granted in Section 7, the right to sublicense
without the consent of the other Party, without obligation to account to the other Party. The laws of the United States with respect to joint ownership of inventions will apply in all jurisdictions giving force and effect to this Agreement.

  
 9.3.2 POZEN will disclose any POZEN
Improvements to Xcel, and Xcel will disclose any Xcel Improvements to POZEN, in each case promptly after the relevant Party 

  

 28 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 
recognizes that any Improvement falls within the definitions set forth in Section 1.44 or 1.64, respectively. Further, each Party will disclose to the other
Party all Improvements made jointly by the disclosing Party and the other Party, or its or their Affiliates or Third Party contractors. The disclosing Party will provide such information in reasonable detail, sufficient to permit an understanding of
the nature of the Improvements by a practitioner reasonably skilled in the relevant technical or scientific area. 
  
 9.3.3 Upon disclosure of a jointly owned Improvement, the Parties will discuss, in good faith, the most appropriate course of
action for the protection of such Improvement. Unless the Parties agree that one Party will assume responsibility for filing and prosecution of any Patents with respect to such Improvement, the Parties will retain joint patent counsel for such
activities (and will share the costs relating thereto equally). 
  
 9.4 Enforcement Rights. 
  
 9.4.1 Notification of Infringement. If either Party learns of any misappropriation or any infringement or threatened infringement of the Licensed Technology, the Xcel Technology or the Product Trademarks in the Field and in
the Territory (the “Product Rights”), such Party will promptly notify the other Party and will provide such other Party with all available evidence of such misappropriation or infringement. 
  
 9.4.2 Enforcement of Patents and Product Rights in
the Territory. 
  
 (a) Xcel will have
the first right, but not the obligation, to institute, prosecute and control at its own expense any action or proceeding with respect to infringement or misappropriation of Product Rights, by counsel of its own choice, and will consult with POZEN on
any actions that Xcel proposes to take in such action or proceeding. POZEN will have the right, at its own expense, to be represented in any such action by counsel of its own choice. 
  
 (b) If Xcel fails to bring an action or proceeding or otherwise take appropriate action in
Xcel’s discretion to abate such infringement or misappropriation in the Field and in the Territory within a period of 90 days of written notice by POZEN to Xcel requesting such action, POZEN will have the right, but not the obligation, to bring
and control, by counsel of its own choice, any such infringement or misappropriation action or proceeding; provided, however, that POZEN will not be entitled to bring any such action or proceeding if [CONFIDENTIAL TREATMENT REQUESTED].
Xcel will cooperate with POZEN in any such action or proceeding brought by POZEN against a Third Party, and will have the right to consult with POZEN and to participate in and be represented by independent counsel in such litigation at its own
expense. 
  
 (c) If a Party brings any
action or proceeding under this Section 9.4.2, the other Party agrees, at the request and expense of the first Party, to be joined as a party plaintiff to the extent necessary to prosecute the action or proceeding and to give the first Party
reasonable assistance and authority to file and prosecute the suit, including reasonable access to the inventors and records related to such action which are under the control of such other Party. 
  

 29 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 9.4.3 Settlement with a Third Party. The Party that controls the
prosecution of a given action under this Section 9.4 will also have the right to control settlement of such action; provided, however, that no settlement will be entered into concerning or affecting the validity or enforceability of (i) the
Licensed Technology or the Product Trademarks without the written consent of POZEN or (ii) the Xcel Technology without the written consent of Xcel. 
  
 9.4.4 Enforcement Costs and Awards. Each Party will bear its own costs incurred in connection with an action or proceeding
brought by a Party pursuant to Section 9.4.2. In the case of an action or proceeding initiated by Xcel, any resulting damage award, after reimbursement of each Party’s expenses, will be deemed Net Sales of Xcel in the Territory and will be
subject to the royalty payment obligations set forth in Section 8.3. In the case of an action or proceeding initiated by POZEN, any resulting damage award, after reimbursement of each Party’s expenses, will be shared between the Parties
proportionate to each Party’s share of costs and expenses incurred in connection with such action or proceeding. 
  
 9.5 Defense and Settlement of Third Party Claims. 
  

9.5.1 Defense. If a Third Party asserts that a patent, trade secret, or other intangible right owned or exclusively
licensed by it is infringed or misappropriated by the manufacture, use, sale, or offer for sale of any Licensed Product in the Field in the Territory during the Term, Xcel will establish a plan for a common defense and manage such common defense
plan, subject to Section 9.5.2 below. Except as provided in Section 9.5.2, each Party will bear its own costs incurred in connection with any such defense, and POZEN will give Xcel reasonable assistance and authority to defend, including reasonable
access to the inventors and records relating to such action which are under the control of POZEN. 
  
 9.5.2 Settlement and Damages. Xcel will control settlement of any claim described in Section 9.5.1 above; provided,
however, that no settlement will be entered into concerning or affecting the validity or enforceability of the Licensed Technology or the Product Trademarks without the written consent of POZEN. Xcel will be responsible for [CONFIDENTIAL
TREATMENT REQUESTED]. 
  
 9.6 Consequence of Patent
Challenge. If Xcel challenges the validity or enforceability of any of the POZEN Patents by any opposition, reexamination request, action for declaratory judgment, nullity action, interference or other attack upon the validity, title or
enforceability thereof before any governmental agency, court or other similar adjudicative forum (any such proceeding, a “Patent Challenge”), such Patent Challenge will be deemed to be a material breach of this Agreement and POZEN
will have the right to terminate this Agreement as provided in Section 14.2 or to terminate all licenses granted under any of the POZEN Patents subject to such Patent Challenge. 
  

	10.	REPRESENTATIONS AND WARRANTIES 

  
 10.1 Mutual Representations and Warranties. Each of the Parties hereby represents and warrants to the other Party as follows: 
  
 10.1.1 Such Party is a corporation duly organized,
validly existing and in good standing under the laws of the state in which it is incorporated; 
  

 30 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 10.1.2 This Agreement is a legal and valid obligation binding upon such Party
and enforceable in accordance with its terms, and the execution, delivery and performance of the Agreement by such Party does not conflict with any agreement, instrument or understanding, oral or written, to which it is a Party or by which it is
bound, nor violate any law or regulation of any court, governmental body or administrative or other agency having jurisdiction over it; 
  
 10.1.3 Such Party has the full corporate power and authority to enter into this Agreement and to carry out the obligations
contemplated hereby; 
  
 10.1.4 To the
best of such Party’s knowledge, neither it, nor any of its employees, officers, subcontractors or consultants who will perform any activities under this Agreement (i) has been debarred or convicted of a crime for which an entity or person could
be debarred under 21 U.S.C. Section 335a, or (ii) is under indictment for a crime for which a person or entity could be debarred under 21 U.S.C. Section 335a; and 
  
 10.1.5 It has taken all necessary corporate action on its part to authorize the execution and
delivery of this Agreement. 
  
 10.2 POZEN
Representations and Warranties. POZEN hereby represents and warrants to Xcel as follows: 
  
 10.2.1 POZEN has not, and during the term of the Agreement will not, [CONFIDENTIAL TREATMENT REQUESTED]; 
  
 10.2.2 POZEN has [CONFIDENTIAL TREATMENT
REQUESTED]; 
  
 10.2.3 POZEN has
[CONFIDENTIAL TREATMENT REQUESTED]; 
  
 10.2.4 To the Knowledge of POZEN, without [CONFIDENTIAL TREATMENT REQUESTED]; 
  
 10.2.5 As of the Effective Date, POZEN has not [CONFIDENTIAL TREATMENT REQUESTED]; 
  
 10.2.6 To the Knowledge of POZEN, each person
[CONFIDENTIAL TREATMENT REQUESTED]; 
  
 10.2.7 To the Knowledge of POZEN, none of the [CONFIDENTIAL TREATMENT REQUESTED]; 
  
 10.2.8 To the Knowledge of POZEN, without [CONFIDENTIAL TREATMENT REQUESTED]; 
  
 10.2.9 As of the Effective Date, the [CONFIDENTIAL
TREATMENT REQUESTED]; 
  
 10.2.10 As
of the Effective Date, POZEN has not [CONFIDENTIAL TREATMENT REQUESTED]; 
  

 31 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 10.2.11 To the Knowledge of POZEN, each [CONFIDENTIAL TREATMENT
REQUESTED]; 
  
 10.2.12 As of the
Effective Date, all [CONFIDENTIAL TREATMENT REQUESTED]; 
  
 10.2.13 As of the Effective Date, (a) POZEN has [CONFIDENTIAL TREATMENT REQUESTED], (b) to the Knowledge of POZEN, POZEN has [CONFIDENTIAL TREATMENT REQUESTED], (c) to the Knowledge of POZEN,
POZEN has [CONFIDENTIAL TREATMENT REQUESTED], and (d) to the Knowledge of POZEN, [CONFIDENTIAL TREATMENT REQUESTED]; 
  
 10.2.14 With respect to the Licensed Technology and any Licensed Product in the Territory, (a) to the Knowledge of POZEN,
[CONFIDENTIAL TREATMENT REQUESTED] and (b) as of the Effective Date, there is [CONFIDENTIAL TREATMENT REQUESTED]; 
  
 10.2.15 As of the Effective Date, (a) POZEN has [CONFIDENTIAL TREATMENT REQUESTED], (b) [CONFIDENTIAL TREATMENT
REQUESTED], and (c) POZEN has [CONFIDENTIAL TREATMENT REQUESTED]; 
  
 10.2.16 [CONFIDENTIAL TREATMENT REQUESTED]; 
  
 10.2.17 To the Knowledge of POZEN, (a) POZEN has [CONFIDENTIAL TREATMENT REQUESTED], and (b) POZEN has received no notice
from [CONFIDENTIAL TREATMENT REQUESTED]; 
  
 10.2.18 As of the Effective Date, there is [CONFIDENTIAL TREATMENT REQUESTED] in connection with (i) any of the Licensed Technology, (ii) any Licensed Product or (iii) POZEN’s performance under this Agreement; and POZEN
is not subject [CONFIDENTIAL TREATMENT REQUESTED] under this Agreement; and 
  
 10.2.19 As of the Effective Date POZEN has [CONFIDENTIAL TREATMENT REQUESTED] that either (i) would be [CONFIDENTIAL
TREATMENT REQUESTED] or (ii) would be [CONFIDENTIAL TREATMENT REQUESTED]. 
  
 10.3 Limitation of Warranty. EXCEPT AS EXPRESSLY STATED IN THIS AGREEMENT, (i) NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY AND (ii) EACH PARTY EXPRESSLY DISCLAIMS ALL IMPLIED WARRANTIES, INCLUDING
WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT, WITH RESPECT TO ANY MATERIALS, INFORMATION, SERVICES, OR LICENSES PROVIDED TO THE OTHER PARTY PURSUANT TO THIS AGREEMENT. 
  
 10.4 Performance by Affiliates. The Parties recognize that each
Party may elect to perform some or all of its obligations under this Agreement through Affiliates; provided, however, that each Party will remain responsible for the performance by such Affiliates and will cause any such Affiliates to accept
in writing to be bound by the terms of this Agreement, and to 

  

 32 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 
comply with the provisions of this Agreement in connection with such performance (such Affiliates being “Performing Affiliates”). Acts or
omissions of any Performing Affiliates or Controlled Affiliates of a Party that, if performed by such Party, would constitute a breach of this Agreement, will be deemed a breach of this Agreement by such Party. Each Party hereby expressly waives any
requirement that the other Party exhaust any right, power or remedy, or proceed against an Affiliate, for any obligation or performance hereunder prior to proceeding directly against such Party. 
  

	11.	INDEMNIFICATION 

  
 11.1 Indemnification by Xcel. Except to the extent of POZEN’s indemnification obligation as set forth in Section 11.2 below, and except
to the extent caused by POZEN’s or its Affiliates’ negligent, reckless or willful acts or omissions, Xcel will indemnify, defend and hold POZEN and its directors, officers, employees, agents and Affiliates harmless from and against any
liabilities, damages, costs or expenses, including reasonable attorneys’ fees (collectively, “Losses”), to the extent arising out of, relating to or resulting from (a) the development, manufacture, use, or sale of any Licensed
Product by or on behalf of Xcel after the Effective Date, including any product liability regardless of whether based on strict liability, breach of warranty, tort or other legal theory, (b) the breach by Xcel of any of its representations,
warranties or obligations contained in this Agreement, or (c) the gross negligence or willful misconduct of Xcel or its Affiliates. 
  
 11.2 Indemnification by POZEN. Except for Xcel’s indemnification obligation as set forth in the preceding Section 11.1, and except to
the extent caused by Xcel’s or its Affiliates’ negligent, reckless or willful acts or omissions, POZEN will indemnify, defend and hold Xcel and its directors, officers, employees, agents and Affiliates harmless from and against any Losses
which arise from any claim, lawsuit or other action to the extent such Losses arise out of, relate to or result from (a) the development, manufacture, use, or sale of any Licensed Product prior to the Effective Date, including any product liability
regardless of whether based on strict liability, breach of warranty, tort or other legal theory, (b) the development, manufacture, use, or sale of any Licensed Product or any Foreign Licensed Product by or on behalf of POZEN other than by or on
behalf of Xcel, including any product liability regardless of whether based on strict liability, breach of warranty, tort or other legal theory, (c) the use of any Xcel Technology or any rights referenced in Section 7.3.3 by POZEN or any sublicensee
of POZEN, (d) the breach by POZEN of any of its representations, warranties or obligations contained in this Agreement, or (e) the gross negligence or willful misconduct of POZEN or its Affiliates. 
  
 11.3 Indemnification Procedures. A Party which intends to claim
indemnification under Section 11.1 or 11.2 of this Agreement (the “Indemnitee”) will promptly notify the other Party (the “Indemnitor”) in writing of any claim, lawsuit or other action in respect of which the
Indemnitee or any of its directors, officers, employees, and Affiliates intend to claim such indemnification within a reasonable period of time after the assertion of such claim; provided, however, that the failure to provide written notice
of such claim within a reasonable period of time will not relieve the Indemnitor of any of its obligations hereunder, except to the extent that the Indemnitor is prejudiced by such failure to provide prompt notice. The Indemnitor will have the right
to assume the complete control of the defense, compromise or settlement of any such claim without the prior written consent of such Indemnitee (although no settlement will be 

  

 33 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 
entered into concerning or affecting the validity or enforceability of (a) the Licensed Technology or the Product Trademarks without the written consent of
POZEN or (b) the Xcel Technology without the written consent of Xcel). The Indemnitor will, if it elects to assume control, at its own expense employ legal counsel to defend the claim at issue. At any time after the Indemnitor has assumed defense of
a claim, the Indemnitor may exercise, on behalf of the Indemnitee, any rights which may mitigate the extent or amount of such claim; provided, however, that the Indemnitee: (x) may, in its sole discretion and at its own expense, employ legal
counsel to represent it (in addition to the legal counsel employed by the Indemnitor) in any such matter, and in such event legal counsel selected by the Indemnitee will be required to confer and cooperate with such counsel of the Indemnitor in such
defense, compromise or settlement for the purpose of informing and sharing information with the Indemnitor; (y) will, at its own expense, make available to Indemnitor those employees, officers and directors of Indemnitee whose assistance, testimony
or presence is necessary, useful or appropriate to assist the Indemnitor in evaluating and in defending any such claim; provided, however, that any such access will be conducted in such a manner as not to interfere unreasonably with the
operations of the businesses of Indemnitee; and (z) will otherwise fully cooperate with the Indemnitor and its legal counsel in the investigation and defense of such claim. 
  
 11.4 Insurance. Each Party will maintain commercially reasonable insurance coverage commensurate with its
obligations under this Agreement. As regards Xcel, such commercially reasonable insurance coverage will include comprehensive general liability insurance coverage, including products liability which carries a minimum limit of not less than
[CONFIDENTIAL TREATMENT REQUESTED] upon the Commercial Launch of the Initial Licensed Product, and Xcel will provide POZEN with a certificate of insurance, naming POZEN as additionally insured, evidencing to POZEN such coverage. 

 

	12.	LIMITATION OF LIABILITY 

  
 IN NO EVENT WILL ANY PARTY BE LIABLE TO THE OTHER PARTY FOR LOST PROFITS, LOSS OF DATA, OR FOR ANY SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL OR
PUNITIVE DAMAGES OF SUCH OTHER PARTY, HOWEVER CAUSED, ON ANY THEORY OF LIABILITY AND WHETHER OR NOT SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, ARISING UNDER ANY CAUSE OF ACTION AND ARISING IN ANY WAY OUT OF THIS AGREEMENT. THE
FOREGOING LIMITATIONS WILL NOT APPLY TO DAMAGES ARISING FROM A BREACH OF SECTION 13 OR AN AWARD OF ENHANCED DAMAGES AVAILABLE UNDER THE PATENT LAWS FOR WILLFUL PATENT INFRINGEMENT. 
  

	13.	CONFIDENTIALITY, PUBLICATIONS, PUBLICITY 

  
 13.1 Confidential Information. Any information or materials communicated by one Party to the other Party pursuant to this Agreement or the
Confidential Disclosure Agreement between the Parties dated February 27, 2003 will be deemed “Confidential Information” of the disclosing Party if (a) such information or materials are marked “confidential” or with
a similar legend, or (b) such information or materials, if disclosed orally or visually, are identified as being confidential at the time of such oral or visual disclosure, and thereafter reduced to writing, marked “confidential” or with a
similar legend, and sent to the other Party within 30 days of such 

  

 34 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 
oral or visual disclosure, or (c) such information or materials would, due to the nature thereof or the circumstances surrounding disclosure, appear to a
reasonable person to be confidential or proprietary. Notwithstanding the preceding sentence, “Confidential Information” will not be deemed to include information that the receiving Party can demonstrate, by competent written proof:

  
 13.1.1 At the time of disclosure is
published or is publicly known or otherwise in the public domain, other than through any act or omission by the receiving Party; 
  
 13.1.2 Was already known to the receiving Party, other than under an obligation of confidentiality or non-use, prior to the time of
disclosure; 
  
 13.1.3 Is disclosed to the
receiving Party in good faith, without an obligation of confidentiality, by a Third Party not under any obligation of confidence with respect to such information; or 
  
 13.1.4 Is independently developed by the receiving Party without use of or reference to the
disclosing Party’s Confidential Information. 
  
 13.2
Treatment of Confidential Information. The Parties agree that during the Term and for 7 years after its expiration or termination for any reason whatsoever, a Party receiving Confidential Information of the other Party will: (a) treat any
such Confidential Information disclosed to it by the other Party as strictly confidential; (b) except as necessary in the performance of this Agreement, not disclose such Confidential Information to Third Parties without the prior written consent of
the other Party, other than to its Affiliates, collaborators or any consultants, provided that such disclosure be under confidentiality agreements with provisions comparable to those contained in this Agreement; (c) not use such Confidential
Information for purposes other than those authorized expressly herein; and (d) use reasonable efforts to prevent inadvertent disclosure of such Confidential Information. 
  
 13.3 Access. Access to Confidential Information will be limited to those employees or consultants of the Party
receiving such information or of such Party’s Affiliates who reasonably require such information in order to carry out activities authorized pursuant to this Agreement. Such employees or consultants will be advised of the confidential nature of
the Confidential Information and the related confidentiality undertaking. 
  
 13.4 Permitted Disclosures. 
  
 13.4.1 Notwithstanding any other provision in this Agreement, a receiving Party may disclose Confidential Information of the disclosing Party to the extent such disclosure is required by law or court order,
provided that the receiving Party gives the disclosing Party prompt written notice of the requirement to disclose and reasonably cooperates with the disclosing Party to seek a protective order or other restrictions on the disclosure of such
Confidential Information of the disclosing Party. Any such required disclosure will be limited only to that Confidential Information that is required to be disclosed and such disclosed Confidential Information will remain Confidential Information
hereunder despite the required disclosure. 
  

 35 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 13.4.2 Notwithstanding anything herein to the contrary, any Party (and any
employee, representative, or other agent of any Party) may disclose to any and all persons, without limitation of any kind, the tax treatment and tax structure of the transactions contemplated by this Agreement and all materials of any kind
(including opinions or other tax analyses) that are provided to it relating to such tax treatment and tax structure; provided, however, that no Party will be permitted to disclose such tax treatment or tax structure to the extent that such
disclosure would constitute a violation of federal or state securities laws. For the purposes of the foregoing sentence, (i) the “tax treatment” of a transaction means the purported or claimed federal income tax treatment of the
transaction, and (ii) the “tax structure” of a transaction means any fact that may be relevant to understanding the purported or claimed federal income tax treatment of the transaction. Thus, for the avoidance of doubt, the Parties
acknowledge and agree that the tax treatment and tax structure of any transaction does not include the name of any Party to a transaction or any sensitive business information (including, without limitation, the name and other specific information
about any Party’s intellectual property or other proprietary assets) unless such information may be related or relevant to the purported or claimed federal income tax treatment of the transaction. 
  
 13.5 Return of Confidential Information. Upon termination or
expiration of this Agreement, each Party hereto and its Affiliates will return all Confidential Information of the other Party in their possession to the other Party; provided, however, that each Party may retain: (a) a single archival copy
of the Confidential Information of the other Party solely for the purpose of determining the extent of disclosure of Confidential Information hereunder and assuring compliance with the surviving provisions of this Agreement; (b) any portion of the
Confidential Information of the other Party which is contained in a Party’s laboratory notebooks; and (c) any portion of the Confidential Information of the other Party which a Party is required by mandatory applicable law to retain.

  
 13.6 Confidentiality of the Agreement Terms.
Neither Party will disclose the terms of this Agreement to any Third Party without the prior written consent of the other Party; provided, however, that either Party may disclose the terms of this Agreement (a) to actual or prospective
investors and corporate partners, (b) to a Party’s accountants, attorneys and other professional advisors, and (c) as required by applicable laws and regulations of the U.S. Securities and Exchange Commission, any stock exchange on which a
Party’s stock is traded and any inter-dealer quotation system on which trading information for a Party’s stock is quoted. As part of any filing of this Agreement pursuant to the foregoing clause (c), the filing Party will provide the other
Party with the opportunity to review and comment on proposed redactions to this Agreement for purposes of such filing (although the filing Party will have no obligation in the event that such redactions are not made or accepted as part of such
filing). 
  
 13.7 Publications. Except for Excepted
Communications and information which has already been published or is otherwise within the public domain, neither Party may present or publish research results arising from this Agreement, including, without limitation, any research results which
relate to the use of the Licensed Technology in the Field, whether in a thesis, scientific publication, conference or otherwise, without the prior written consent of the other Party. Intended presentations or publications will be presented in
writing to the other Party in the English language for review and comment at least 30 days prior to the time which the presentation or publication is proposed for submission to any Third Party. Within such 30-day 

  

 36 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 
period and at least 5 business days prior to the time which the presentation or publication is proposed for submission to any Third Party, the other Party
will provide notice whether it has any comments or objection to the proposed presentation or publication. The submitting Party will consider in good faith all comments by the reviewing Party. If a reasonable objection is raised (because, for
example, the contents of the presentation or publication contain patentable subject matter for which patent protection should be sought, or because the presentation or publication discloses Confidential Information of the other Party which
constitutes proprietary trade secrets or Know-How), then submission of the presentation or publication will be delayed, unless and until such time as consent to submission of the presentation or publication is given. Each Party may be acknowledged
on any publication or presentation by the other Party in accordance with generally accepted rules of authorship. 
  
 13.8 Publicity. Promptly following the Effective Date, the Parties will publish a mutually agreed joint press release. Neither Party will
make any public announcement concerning the existence of or the terms of this Agreement, without the prior written approval of the other Party with regard to the form, content and precise timing of such announcement, except such as may be required
to be made by either Party in order to comply with applicable law, regulations, court order, or tax or securities filings. Prior to any such public announcement, the Party wishing to make the announcement will submit a draft of the proposed
announcement to the other Party not less than 3 business days in advance to enable the other Party to consider and comment thereon. Notwithstanding anything to the contrary in this Agreement, nothing in this Section 13.8 is intended to prohibit
either Party from republishing or restating information relating to this Agreement that has already been approved by the other Party for use in a prior press release or public announcement. 
  

	14.	TERM AND TERMINATION 

  
 14.1 Term of the Agreement. The term of this Agreement (the “Term”) will commence on the Effective Date and, unless
terminated earlier pursuant to Section 3.4.4 or this Section 14, will expire at the end of the Royalty Term. 
  
 14.2 Termination for Material Breach. In the event of a material breach of this Agreement by either Party which is not cured within 60 days
following receipt of written notice of such breach from the non-breaching Party (or, as applicable, (i) 15 days following receipt of such written notice in the event the breach involves a payment which is not the subject of a bona fide dispute or
(ii) 180 days following receipt of such written notice if the breaching party is attempting to cure the breach at issue and is exercising Commercially Reasonable Efforts with respect thereto), the non-breaching Party will have the right to terminate
this Agreement by written notification to the other Party, effective immediately upon receipt. 
  
 14.3 Termination for [CONFIDENTIAL TREATMENT REQUESTED]. If this Agreement terminates pursuant to Section 3.1.5, [CONFIDENTIAL TREATMENT REQUESTED]. 
  
 14.4 [CONFIDENTIAL TREATMENT REQUESTED]. [CONFIDENTIAL
TREATMENT REQUESTED] terminate this Agreement [CONFIDENTIAL TREATMENT REQUESTED] not less than [CONFIDENTIAL TREATMENT REQUESTED] prior to the 

  

 37 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 
date of termination; provided that [CONFIDENTIAL TREATMENT REQUESTED] of the first Licensed Product [CONFIDENTIAL TREATMENT REQUESTED] under
this Agreement. Promptly [CONFIDENTIAL TREATMENT REQUESTED], the Parties will meet to prepare a transition plan for the orderly transfer of the Commercialization and the development (if any) of the Licensed Products from Xcel to POZEN or a
Third Party designated by POZEN. If POZEN or a Third Party designated by POZEN are in a position to assume such Commercialization or development prior to the termination date [CONFIDENTIAL TREATMENT REQUESTED] in accordance with this Section
14.4, such termination date will be accelerated upon POZEN’s request. 
  

	15.	CONSEQUENCES OF TERMINATION 

  
 15.1 General. No termination of this Agreement will relieve any Party from any liability which, at the time of such termination, has already
accrued to the other Party or which is attributable to a period prior to such termination, nor preclude either Party from pursuing any rights and remedies it may have under this Agreement or at law or in equity which accrued or are based upon any
event occurring prior to such termination. 
  
 15.2
Termination Prior to Expiration. If this Agreement is terminated prior to its expiration, then: 
  
 (a) the rights and licenses granted by POZEN to Xcel under this Agreement will terminate immediately; 
  
 (b) all Regulatory Approvals will be assigned and
transferred by Xcel to POZEN, and Xcel will promptly take all actions and execute such documents as requested by POZEN to effect such transfer to POZEN; 
  
 (c) Xcel will transfer to POZEN such quantities of Licensed Product in Xcel’s inventory as may be requested by POZEN no later
than 30 days of such termination and POZEN will pay to Xcel an amount equivalent to [CONFIDENTIAL TREATMENT REQUESTED] such Licensed Product, provided POZEN will buy all such Licensed Product that has at least [CONFIDENTIAL TREATMENT
REQUESTED] of shelf life at the time this Agreement is terminated and Xcel will be entitled, notwithstanding any provision herein to the contrary, to sell (or have sold) all other Licensed Product in its inventory for up to [CONFIDENTIAL
TREATMENT REQUESTED] following the termination of this Agreement provided that the terms of this Agreement, including Xcel’s royalty payment obligations in Section 8, will apply with respect to such sales (excluding any transfers to POZEN)
as if this Agreement was still in effect; 
  
 (d) at POZEN’s election, Xcel will transfer and cause its Affiliates and agents to transfer to POZEN any or all Promotional Materials, and POZEN will (i) pay to Xcel an amount [CONFIDENTIAL TREATMENT REQUESTED] of such
Promotional Materials, and (ii) sticker-over any Xcel Trademarks prior to the use of any such Promotional Materials; 
  
 (e) POZEN will, insofar as Xcel is concerned, have the exclusive right to develop, make, have made, use, and Commercialize Licensed
Products in the Territory alone or with or through a Third Party; and 
  

 38 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 (f) the licenses granted to POZEN in Section 7.3 are worldwide (but
non-exclusive in the Territory), fully paid, perpetual and irrevocable. 
  
 15.3 Manufacturing Agreements. With respect to any agreements entered into by Xcel with [CONFIDENTIAL TREATMENT REQUESTED]: (i) if this Agreement is terminated by POZEN pursuant to Section 14.2, POZEN will assume such
agreements (if permitted by such agreements); (ii) if this Agreement is terminated by Xcel pursuant to Section 3.4.4 or Section 14.2, POZEN will assume such agreements if Xcel so elects (and if permitted by such agreements); and (iii) if this
Agreement is terminated by [CONFIDENTIAL TREATMENT REQUESTED] pursuant to Section 14.4, [CONFIDENTIAL TREATMENT REQUESTED] may assume such agreements if [CONFIDENTIAL TREATMENT REQUESTED] so elects (and if permitted by such
agreements). 
  
 15.4 Licenses Upon Expiration. Upon
expiration of this Agreement pursuant to Section 14.1: (a) the licenses granted to Xcel in Section 7.1 are fully paid, perpetual and irrevocable, subject to the provisions of Section 5.4 relating to payment of a royalty for use of the Product
Trademarks; and (b) the licenses granted to POZEN in Section 7.3 are fully paid, perpetual and irrevocable. 
  
 15.5 Survival. 
  
 15.5.1 In the event of any expiration or termination of this Agreement, the following sections will survive (together with the
definitions of any defined terms used therein as well as any other provisions to the extent cross-referenced or invoked thereby): Sections 3.5, 3.7, 4.1.2 (unless this Agreement is terminated pursuant to Section 3.4.4 or 3.1.5 or pursuant to
POZEN’s breach under Section 14.2), 5.4.6, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.1, 10.3, 11, 12, 13, 15, 16, and 17. All other provisions, including all rights and obligations thereunder, will terminate and be of no further force and effect.

  
 15.5.2 Section 5.4 (together with the
definitions of any defined terms used therein as well as any other provisions to the extent cross-referenced or invoked thereby) and Section 9 (with respect to the provisions pertaining to the Product Trademarks and Designated POZEN Trademarks,
together with the applicable definitions of any defined terms used therein as well as any other applicable provisions cross-referenced or invoked thereby) will survive the expiration of this Agreement. 
  

	16.	DISPUTE RESOLUTION 

  
 16.1 Discussions. The Parties will try to settle their differences amicably between themselves. In the event of any controversy or claim
arising out of or relating to any provision of this Agreement or the performance or alleged non-performance of a Party of its obligations under this Agreement (a “Dispute”), a Party may notify the other Party in writing of such
Dispute. If the Parties are unable to resolve the Dispute within 20 days of receipt of the written notice by the other Party, such Dispute will be referred to the Chief Executive Officers of each of the Parties (or their respective designees) who
will use their good faith efforts to resolve the Dispute within 10 days after it was referred to the Chief Executive Officers. 
  

 39 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 16.2 Arbitration. 
  
 16.2.1 Any Dispute that is not resolved as provided in the preceding Section 16.1, whether before or
after termination of this Agreement, will be referred to binding arbitration under the rules of the American Arbitration Association, to the extent such rules are not inconsistent with this Section 16.2. Judgment upon the award of the arbitrators
may be entered in any court having jurisdiction thereof or such court may be asked to judicially confirm the award and order its enforcement, as the case may be. 
  
 16.2.2 The demand for arbitration will be made within a reasonable time after the Dispute has arisen,
and in any event will not be made after the date when institution of legal or equitable proceedings, based on such Dispute, would be barred by the applicable statute of limitations. The arbitration panel will consist of three (3) arbitrators, one
(1) of whom will be appointed by each Party. The two (2) arbitrators thus appointed will choose the third arbitrator; provided, however, that if the two (2) arbitrators are unable to agree on the appointment of the third arbitrator, either
arbitrator may petition the American Arbitration Association to make the appointment. 
  
 16.2.3 The provisions of Federal Rules of Civil Procedure sections governing discovery are incorporated in and made a part of this
Agreement. Depositions may be taken and full discovery may be obtained in any arbitration commenced under this provision. 
  
 16.2.4 The arbitrators will, within 15 days after the conclusion of the arbitration hearing, issue a written award and statement of
decision describing the essential findings and conclusions on which the award is based, including the calculation of any damages awarded. The Arbitrator are authorized to award compensatory damages consistent with the terms of this Agreement, but
are NOT authorized (i) to award non-economic damages, such as for emotional distress, pain and suffering or loss of consortium, (ii) to award punitive damages, or (iii) to reform, modify or materially change this Agreement or any other agreements
contemplated hereunder; provided, however, that the damage limitations described in parts (i) and (ii) of this sentence will not apply if such damages are statutorily imposed. The arbitrators are authorized to grant any temporary, preliminary
or permanent equitable remedy or relief they deem just and equitable and within the scope of this Agreement, including, without limitation, an injunction or order for specific performance. 
  
 16.2.5 The place of arbitration will be New York, New
York. Each Party will bear and pay its own expenses incurred in connection with any dispute resolution under this Section 16.2. 
  
 16.3 Patents and Other Intellectual Property. Notwithstanding any provision of this Agreement to the contrary, any Dispute relating to a
Party’s intellectual property rights or Confidential Information will be submitted exclusively to any court of competent jurisdiction in the State of New York and, by execution and delivery of this Agreement, each party (a) accepts, generally
and unconditionally, the exclusive jurisdiction of such courts and any related appellate court, and irrevocably agrees to be bound by any judgment rendered thereby as contemplated by this Section 16.3, and (b) irrevocably waives any objection it may
now or hereafter have as to the 

  

 40 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 
venue of any such suit, action or proceeding brought in such a court or that such a court is an inconvenient forum. 
  

	17.	MISCELLANEOUS 

  
 17.1 Further Assurances. At any time during the Term, Xcel and POZEN each will, at the request of the other Party, use reasonable efforts to
(a) deliver to the other Party such records, data or other documents consistent with the provisions of this Agreement, (b) execute, and deliver or cause to be delivered, all such assignments, consents, documents or further instruments of transfer or
license, and (c) take or cause to be taken all such other actions, as a Party may reasonably deem necessary or desirable in order for such Party to obtain the full benefits of this Agreement and the transactions contemplated hereby. 
  
 17.2 Assignment. Neither Party will assign its rights or
obligations under this Agreement to any Third Party, without the prior written consent of the other Party; except that either Party may assign such rights and obligations to a Third Party in connection with a merger, acquisition, consolidation,
transfer or sale of all or substantially all of the assets of a Party (collectively, a “Change of Control Event”) provided that such Third Party agrees in writing to be bound by all of the terms and conditions of this Agreement. All
permitted assignments by either Party of any of its rights under this Agreement will be subject to all of the terms and conditions of this Agreement. Any purported assignment not permitted under the terms of this Agreement will be null, void, and of
no effect. Notwithstanding anything in this Agreement, the POZEN Know-How, POZEN Improvements, and POZEN Patents, as well as the Xcel Know-How, Xcel Improvements, and Xcel Patents do not include any intellectual property held by a permitted
successor prior to the Change of Control Event of the relevant Party. 
  
 17.3 Independent Contractors. The Parties are independent contractors. Nothing contained herein will constitute either Party the agent of the other Party for any purpose whatsoever, or constitute the Parties as partners or
joint venturers. Employees of each Party remain employees of said Party and will be considered at no time agents of or owing a fiduciary duty to the other Party. Neither Party will have any implied right or authority to assume or create any
obligations on behalf of or in the name of the other Party or to bind the other Party to any other contract, agreement or undertaking with any Third Party. 
  
 17.4 Waiver. The failure of either Party to enforce any provision of this Agreement at any time will not be construed as a present or future
waiver of such or any other provision of this Agreement. The express waiver by either Party of any provision or requirement hereunder will not operate as a future waiver of such or any other provision or requirement and will be effective only if set
forth in a written instrument signed by a duly authorized representative of the Party waiving such provision or requirement. 
  
 17.5 Amendment. The Parties may amend, modify or alter any of the provisions of this Agreement, but such amendment, modification or
alteration will be valid and binding on either Party only if made by a written instrument that explicitly refers to this Agreement and that is signed by a duly authorized representative of each Party. 
  

 41 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 17.6 Severability. In the event that any provision in this Agreement is held to be
unlawful or invalid in any jurisdiction, the meaning of such provision will be construed to the greatest extent possible so as to render it enforceable. If no such construction can render such provision enforceable, it will be severed. The remainder
of this Agreement will remain in full force and effect, and the Parties will negotiate in good faith a reasonable substitute provision that is valid and enforceable in such jurisdiction. If the Parties are unable to agree on a substitute provision,
and if the unlawful or invalid provision was an essential element of this Agreement without which one of the Parties would not have entered into this Agreement, as evidenced by this Agreement as a whole, then such Party may terminate this Agreement
by written notice to the other Party effective upon receipt. 
  
 17.7 Notice. All notices hereunder must be given in writing and will be deemed given if delivered personally or by facsimile transmission (receipt confirmed), mailed by registered or certified mail (return receipt requested)
with postage prepaid, or sent by express courier service (FedEx or other reputable, internationally recognized courier service), to the Parties at the following addresses (or at such other address for a Party as will be specified by like notice;
provided that notices of a change of address will be effective only upon receipt thereof): 
  

	 If to POZEN:
	  	POZEN, Inc.
	 	  	1414 Raleigh Road
	 	  	Suite 400
	 	  	Chapel Hill, NC 27517
	 	  	Attention: President
	 	  	Facsimile: (919) 913-1039
		
	 With copies to:
	  	Cooley Godward LLP
	 	  	One Freedom Square
	 	  	Reston Town Center
	 	  	11951 Freedom Drive
	 	  	Reston, VA 20190-5656
	 	  	Attention: Matthias Alder
	 	  	Facsimile: (703) 456-8100
		
	 If to Xcel:
	  	Xcel Pharmaceuticals, Inc.
	 	  	6363 Greenwich Drive
	 	  	Suite 100
	 	  	San Diego, CA 92122
	 	  	Attention: Chief Financial Officer
	 	  	Facsimile: (858) 202-2799
		
	 With copies to:
	  	Pillsbury Winthrop LLP
	 	  	11682 El Camino Real
	 	  	Suite 200
	 	  	San Diego, CA 92130
	 	  	Attention: Mike Hird
	 	  	Facsimile: (858) 509-4010

  
  

 42 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 17.8 Force Majeure. Neither Party will be deemed to be in breach of this Agreement as a
result of default, delay or failure to perform by such Party which is due to any cause beyond the reasonable control of such Party, including without limitation, fire, earthquake, acts of God, severe weather, acts of war, strikes, lockouts or other
labor disputes, riots, civil disturbances, actions or inactions of governmental authorities (except actions in response to a breach of applicable laws by such Party), or epidemics. In the event of any such force majeure, the Party affected will
promptly notify the other Party, will use commercially reasonable efforts to overcome such force majeure, and will keep the other Party informed with respect thereto. If such force majeure continues for a period of more than 180 days, the Party not
subject to such force majeure may terminate this Agreement by written notice to the other Party. 
  
 17.9 Counterparts. This Agreement may be executed by the Parties in one or more identical counterparts, all of which together will
constitute this Agreement. If this Agreement is executed in counterparts, no signatory hereto will be bound until both Parties have duly executed a counterpart of this Agreement. Delivery of an executed counterpart of a signature page of this
Agreement by facsimile will be effective as delivery of the originally executed counterpart of this Agreement. 
  
 17.10 Governing Law. This Agreement will be governed by, and construed an interpreted in accordance with, the laws of the State of New York
without giving effect to any choice of law rule that would cause the application of the laws of any jurisdiction other than the internal laws of the State of New York to the right and duties of the Parties. 
  
 17.11 Construction. Unless used in combination with the word
“either,” the word “or” is used throughout this Agreement in the inclusive sense (and/or). The captions of this Agreement are for convenience of reference only and in no way define, describe, extend or limit the scope or intent
of this Agreement or the intent of any provision contained in this Agreement. References to Sections are references to Sections of this Agreement. The term “including” as used herein will mean including, without limiting the generality of
any description preceding such term. Whenever, in this Agreement, the consent, approval or agreement of the other Party is required in order for a Party to take certain actions, the Parties agree that such consent, approval or agreement may not be
unreasonably withheld or delayed. No rule of strict construction will be applied against either Party. Unless expressly provided herein to the contrary, all time limits, notice periods, deadlines or the like described herein will be governed by the
follow parameters: (i) for all time periods that are 5 days in length or less, such periods will be deemed to be business days, and (ii) for all time periods greater than 5 days in length will be deemed to be calendar days. References to
“$” or “dollars” mean US dollars. 
  
 17.12
Entire Agreement. This Agreement, including any Exhibits attached hereto, constitutes the entire agreement of the Parties with respect to the subject matter hereof, and supersedes all prior and contemporaneous agreements, understandings
and negotiations, whether oral or written, with respect to such subject matter. 
  
 The Parties have caused this Agreement to be executed as of the Effective Date by signature of their duly authorized representatives. 
  

 43 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 POZEN Inc. 
  

		
	By:	 	/s/    JOHN R. PLACHETKA        
	 	

	 	 	John R. Plachetka, Pharm. D.
	 Title:
	 	Chairman, President and CEO

  
  

	Xcel Pharmaceuticals, Inc.
		
	By:	 	/s/    MICHAEL T. BORER        
	 	

	 	 	Michael T. Borer
	 Title:
	 	President and CEO

  

 44 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 EXHIBITS 
  
 Exhibit A – [CONFIDENTIAL TREATMENT REQUESTED] 
  
 Exhibit B – Outline of Autoinjector Development Plan 
  
 Exhibit C – Outline of Marketing Plan for Initial Licensed Product 
  
 Exhibit D – Certain Pozen Patents 
  
 Exhibit E – Certain Xcel Patents 
  
 Exhibit F – Co-Promotion Agreement Dispute Resolution Procedure 
  
 The exhibits have been omitted from this Agreement as filed with the Securities and Exchange Commission (the “SEC”). The omitted information is considered
immaterial from an investor’s perspective. The Registrant will furnish supplementally a copy of any of the documents to the SEC upon the request of the SEC. 
  

 45Warrant to Purchase Shares of Common Stock

 EXHIBIT 4.17 
  
 WARRANT 
  
 THIS WARRANT HAS BEEN ISSUED AND THE SHARES OF COMMON STOCK WHICH MAY BE PURCHASED PURSUANT TO THE EXERCISE OF THE RIGHTS UNDER THIS WARRANT HAVE BEEN ACQUIRED FOR
INVESTMENT AND NOT FOR DISTRIBUTION, AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. SUCH SECURITIES MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED IN THE ABSENCE OF A REGISTRATION
STATEMENT IN EFFECT WITH RESPECT THERETO UNDER SUCH ACT UNLESS SOLD PURSUANT TO RULE 144 OF SUCH ACT OR UNLESS SUCH SALE, OFFER, PLEDGE, HYPOTHECATION OR TRANSFER IS OTHERWISE EXEMPT FROM REGISTRATION. 
  
 WARRANT TO PURCHASE SHARES OF COMMON STOCK 
 OF 
 HEALTHETECH, INC. 

 
 Dated as of August 28, 2003 
  

	No. CS-13	 	Warrant to Purchase
	 	 	100,000 Shares of
	 	 	Common Stock of the Company
	 	 	(subject to adjustment)

  
 THIS CERTIFIES THAT,
for value received, MARC USA/Pittsburgh, Inc. (the “Holder”) is entitled, subject to the terms and conditions set forth below, to purchase from HealtheTech, Inc., a Delaware corporation (the “Company”), up to
one-hundred thousand (100,000) shares of the Company’s Common Stock, $0.001 par value per share (the “Shares”), in the amounts and at the price per share set forth in Section 1 below, subject to the provisions and upon the
terms and conditions set forth herein. The term “Warrant” as used herein shall include this Warrant and any warrants delivered in substitution or exchange therefore as provided herein.  
  
 1. Number, Price and Expiration of the Shares. 
  
 (a) The Holder shall have the right to purchase up to a total of one-hundred
thousand (100,000) of the Shares (as may be adjusted pursuant hereto), at an exercise price of $7.50 per share, which right shall terminate, to the extent not exercised, at 5:00 p.m., Mountain Time, on August 27, 2006. 
  
 2. Exercise of Warrant. 
  
 (a) Exercise. The purchase rights represented by this Warrant may be
exercised at the election of the Holder, in whole or in part, in accordance with Section 1 and prior to the expiration of this Warrant, by (i) the tender to the Company at its principal office (or such other office or agency of the Company as it may
designate by notice in writing to the Holder at 
  

 1. 

 
the address of the Holder appearing on the books of the Company) of a notice of exercise in the form attached hereto as Exhibit A (the
“Notice of Exercise”), duly completed and executed on behalf of the Holder, together with the surrender of this Warrant, and (ii) the payment to the Company of an amount equal to the applicable exercise price(s) multiplied by the
number of Shares being purchased by wire transfer or certified, cashier’s or other check acceptable to the Company and payable to the order of the Company. 
  
 (b) Stock Certificates. The rights under this Warrant shall be deemed to have been exercised and the Shares shall be
deemed to have been issued immediately prior to the close of business on the date of its tender for exercise as provided above, and the person entitled to receive the Shares issuable upon such exercise shall be treated for all purposes as the holder
of record of such Shares as of the close of business on such date. As promptly as reasonably practicable on or after such date, the Company shall direct the Company’s transfer agent to issue and deliver to the person or persons entitled to
receive the same a certificate or certificates for that number of shares issuable upon such exercise. In the event that the rights under this Warrant are exercised in part and have not expired, the Company shall execute and deliver a new Warrant
with the same terms and conditions for the number of Shares that remain subject to this Warrant. 
  
 (c) Taxes. In no event shall the Company be required to pay any tax which may be payable in respect of any transfer involved in the issue and
delivery of any certificate in a name other than that of the Holder, and the Company shall not be required to direct the Company’s transfer agent to issue or deliver any such certificate unless and until the person or persons requesting the
issue thereof shall have paid to the Company the amount of such tax or shall have established to the satisfaction of the Company that such tax has been paid. 
  
 3. No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of the rights
under this Warrant. In lieu of such fractional share to which the Holder would otherwise be entitled, the Company shall make a cash payment equal to the applicable exercise price(s) multiplied by such fraction. 
  
 4. Replacement of Warrant. On receipt of evidence reasonably
satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory in form and substance to the Company or, in the
case of mutilation, on surrender and cancellation of this Warrant, the Company at the expense of the Holder shall execute and deliver, in lieu of this Warrant, a new warrant of like tenor and amount. 
  
 5. Representations and Warranties of the Holder. 
  
 (a) Investment Intent. The Holder is acquiring the Securities Warrant
and the Shares issuable upon exercise of the Warrant, for investment for his own account, not as a nominee or agent, and not with the view to, or for resale in connection with, any distribution thereof. 
  
 (b) Investment Experience. The Holder has substantial experience in
evaluating and investing in private placement transactions of securities in companies similar to the Company so that he is capable of evaluating the merits and risks of his investment in the Company and has the capacity to protect his own interests.

  

 2. 

 (c) Speculative Nature of Investment. The Holder acknowledges that his investment in the Company
is highly speculative and entails a substantial degree of risk and the Holder is in a position to lose the entire amount of such investment. 
  
 (d) Access to Data. The Holder has had an opportunity to discuss the Company’s business, management and financial affairs with the
Company’s management. The Holder has also had an opportunity to ask questions of officers of the Company, which questions were answered to his satisfaction. The Holder understands that such discussions, as well as any information issued by the
Company, were intended to describe certain aspects of the Company’s business and prospects, but were not necessarily a thorough or exhaustive description. The Holder acknowledges that any business plans prepared by the Company have been, and
continue to be, subject to change and that any projections included in such business plans or otherwise are necessarily speculative in nature, and it can be expected that some or all of the assumptions underlying the projections will not materialize
or will vary significantly from actual results. 
  
 (e)
Accredited Investor. The Holder is an “accredited investor” within the meaning of Regulation D, Rule 501(a), promulgated by the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities
Act”). 
  
 (f) Residency. The residency of the
Holder is correctly set forth on the signature page hereto. 
  
 (g) Restriction on Resales. The Holder acknowledges that the Warrant and the Shares issuable upon exercise of the Warrant must be held indefinitely unless subsequently registered under the Securities Act or unless an exemption from
such registration is available. The Holder further understands that there is no assurance that any exemption from registration under the Securities Act will be available or, if available, that such exemption will allow the Holder to dispose of or
otherwise transfer any or all of the Securities under the circumstances, in the amounts or at the times the Holder might propose. 
  
 (h) Rule 144. The Holder is aware of the provisions of Rule 144 promulgated under the Securities Act which permit limited resale of shares
purchased in a private placement subject to the satisfaction of certain conditions, including among other things, the existence of a public market for the shares, the availability of certain current public information about the Company, the resale
occurring not less than one year after a party has purchased and paid for the security to be sold, the sale being effected through a “broker’s transaction” or in transactions directly with a “market maker” and the number of
shares being sold during any three-month period not exceeding specified limitations. The Holder acknowledges that, in the event all of the requirements of Rule 144 are not met, registration under the Securities Act or an exemption from registration
will be required for any disposition of the Securities. The Holder understands that, although Rule 144 is not exclusive, the Securities and Exchange Commission has expressed its opinion that persons proposing to sell restricted securities received
in a private offering other than in a registered offering or pursuant to Rule 144 will have a substantial burden of proof in establishing that an exemption from registration is available for such offers or sales and that such persons and the brokers
who participate in the transactions do so at their own risk. 
  
 (i) Authorization. 
  
 (i) The Holder has all
requisite power and authority to execute and deliver this Warrant, to purchase the Shares issuable upon exercise of the rights under this Warrant and to carry out and perform his obligations under the terms and conditions of this 

  

 3. 

 
Warrant. All action on the part of the Holder necessary for the authorization, execution, delivery and performance of this Warrant, and the performance of
all of the Holder’s obligations under this Warrant, has been taken or will be taken prior to the purchase of this Warrant. 
  
 (ii) This Warrant, when executed and delivered by the Holder, will constitute a valid and legally binding obligation of the Holder, enforceable in
accordance with its terms except: (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, and (ii) as limited by laws relating
to the availability of specific performance, injunctive relief or other equitable remedies or by general principles of equity. 
  
 (iii) No consent, approval, authorization, order, filing, registration or qualification of or with any court, governmental authority or third person is
required to be obtained by the Holder in connection with the execution and delivery of this Warrant or the performance of the Holder’s obligations hereunder. 
  
 (j) Brokers and Finders. The Holder has not engaged any brokers, finders or agents in connection with this Warrant,
and the Company has not incurred and will not incur, directly or indirectly, as a result of any action taken by the Holder, any liability for brokerage or finders’ fees or agents’ commissions or any similar charges in connection with this
Warrant. 
  
 (k) Investor Counsel. The Holder acknowledges
that he has had the opportunity to review this Warrant and the exhibits attached hereto and the transactions contemplated by this Warrant with his own legal counsel. The Holder is relying solely on such counsel and not on any statements or
representations of the Company or its agents for legal advice with respect to this investment or the transactions contemplated by this Warrant. 
  
 (l) Tax Advisors. The Holder has reviewed with his own tax advisors the U.S. federal, state, local and foreign tax consequences of this investment
and the transactions contemplated by this Warrant. With respect to such matters, the Holder relies solely on such advisors and not on any statements or representations of the Company or any of its agents, written or oral. The Holder understands that
he (and not the Company) shall be responsible for his own tax liability that may arise as a result of this investment or the transactions contemplated by this Warrant. 
  
 6. Transfer of Warrants; Restrictions on Transfer. 
  
 (a) Warrant Register. The Company shall maintain a register (the “Warrant Register”) containing the
name and address of the Holder or Holders. Any Holder of this Warrant or any portion thereof may change its address as shown on the Warrant Register by written notice to the Company requesting such change. Any written notice or written communication
required or permitted to be given to the Holder may be delivered or given by any method provided in Section 11(d) hereof. Until this Warrant is transferred on the Warrant Register, the Company may treat the Holder as shown on the Warrant Register as
the absolute owner of this Warrant for all purposes, notwithstanding any notice to the contrary. 
  
 (b) Warrant Agent. The Company may, by notice to the Holder, appoint an agent for the purpose of maintaining the Warrant Register referred to in
Section 6(a) above, issuing the Shares or other securities then issuable upon the exercise of the rights under this Warrant, exchanging this Warrant, replacing this Warrant or any or all of the foregoing. Thereafter, any such registration, issuance,
exchange or replacement, as the case may be, shall be made at the office of such agent. 
  

 4. 

 (c) Transferability and Non-negotiability of Warrant. This Warrant may not be transferred or
assigned in whole or in part without compliance with all applicable federal and state securities laws by the transferor and the transferee. Subject to the provisions of this Warrant with respect to compliance with the Securities Act and limitations
on assignments and transfers, including without limitation compliance with the restrictions on transfer set forth in Section 6(e) hereof, title to this Warrant may be transferred by endorsement (by the transferor and the transferee executing the
assignment form (the “Assignment Form”) attached hereto as Exhibit B) and delivery in the same manner as a negotiable instrument transferable by endorsement and delivery. 
  
 (d) Exchange of Warrant upon a Transfer. On surrender of this Warrant
for exchange and a properly endorsed Assignment Form, and subject to the provisions of this Warrant with respect to compliance with the Securities Act and limitations on assignments and transfers, the Company shall issue to or on the order of the
Holder a new warrant or warrants with the same terms and conditions, in the name of the Holder or such other individual or entity as the Holder (on payment by the Holder of any applicable transfer taxes) may direct, for the number of shares Shares
issuable upon exercise of the rights hereunder and the Company shall register any such transfer upon the Warrant Register. This Warrant and the Shares issuable upon exercise of the rights under this Warrant must be surrendered to the Company or its
warrant or transfer agent, as applicable, as a condition precedent to the sale, pledge, hypothecation or any other transfer of any interest in any of the securities represented hereby. Upon the transfer of this Warrant pursuant to the terms of this
Section 6, the transferee shall be a “Holder” under the terms hereof. 
  
 (e) Restrictions on Transfer of Warrants and Shares; Compliance with Securities Laws. 
  
 (i) The Holder agrees not to make any disposition of all or any portion of
the Shares or this Warrant unless and until, and it shall be a condition to the transfer of all or any portion of the Shares or this Warrant that: (1) there is then in effect a registration statement under the Securities Act covering such proposed
disposition and such disposition is made in accordance with such registration statement or (2) (A) the Holder shall have notified the Company of the proposed disposition and shall have furnished the Company with a detailed statement of the
circumstances surrounding the proposed disposition, (B) the transferee shall have agreed in writing to be bound by and subject to the terms, conditions, restrictions, obligations and other limitations set forth in this Warrant to the same extent as
if such transferee were the original Holder hereunder, (C) the transferee shall have confirmed to the satisfaction of the Company in writing, substantially in the form attached hereto as Exhibit C, that the Shares or the Warrant
purchased are being acquired solely for the transferee’s own account and not as a nominee for any other party, for investment and not with a view toward distribution or resale and that the transferee shall have confirmed such other matters
related thereto as may be reasonably requested by the Company, and (D) if requested by the Company, the Holder shall have furnished the Company with an opinion of counsel, reasonably satisfactory to the Company, that such disposition will not
require registration of the Warrant or such Shares under the Securities Act. This Warrant or any portion hereof and any Shares issuable pursuant to the exercise of the rights under this Warrant that are transferred to a transferee shall be subject
to the terms, conditions, restrictions, obligations and other limitations set forth herein. 
  

 5. 

 (ii) Unless the rights under this Warrant are exercised pursuant to an effective registration statement
under the Securities Act that includes the Shares with respect to which the Warrant was exercised, it shall be a condition to any exercise of the rights under this Warrant that the Holder shall have confirmed to the satisfaction of the Company in
writing, substantially in the form attached hereto as Exhibit C, that the Shares so purchased are being acquired solely for the Holder’s own account and not as a nominee for any other party, for investment and not with a view
toward distribution or resale and that the Holder shall have confirmed such other matters related thereto as may be reasonably requested by the Company. 
  
 (iii) This Warrant and all Shares issued upon exercise hereof shall be stamped or imprinted with a legend in substantially the following form (in
addition to any legend required by state securities laws): 
  
 “THESE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT FOR DISTRIBUTION, AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. SUCH SECURITIES MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED,
HYPOTHECATED OR OTHERWISE TRANSFERRED IN THE ABSENCE OF A REGISTRATION STATEMENT IN EFFECT WITH RESPECT THERETO UNDER SUCH ACT UNLESS SOLD PURSUANT TO RULE 144 OF SUCH ACT OR UNLESS SUCH SALE, OFFER, PLEDGE, HYPOTHECATION OR TRANSFER IS OTHERWISE
EXEMPT FROM REGISTRATION.” 
  
 (f) This Warrant may not be
transferred in part unless such transfer is to a transferee who, pursuant to such transfer, receives the right to purchase at least five thousand (5,000) Shares hereunder (as adjusted from time to time in accordance with Section 9 hereof).

  
 7. Reservation of Stock. The Company agrees during the
term the rights under this Warrant are exercisable to reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Shares upon the exercise of the rights under this Warrant and, from time to
time, to use its best efforts to amend its Certificate of Incorporation to provide sufficient reserves of shares of Common Stock issuable upon exercise of the rights under the Warrant. 
  
 8. Expiration; Early Termination. This Warrant shall expire on August 27, 2003, and shall be void thereafter.
Notwithstanding the foregoing, this Warrant shall terminate immediately prior to the voluntary liquidation, dissolution or winding up of the Company. 
  
 9. Adjustment Rights. The number and kind of shares purchasable hereunder and the applicable exercise price(s) therefore are subject to adjustment
from time to time, as follows: 
  
 (a) Merger. If at any
time after the date hereof there shall be any reorganization, recapitalization, merger or consolidation involving the Company in which shares of the Company’s stock (other than a reorganization, recapitalization, merger or consolidation or a
related combination, reclassification, exchange, capital reorganization, subdivision of securities or other transaction otherwise provided for herein) are converted into or exchanged for securities, cash or other property, other than as would cause
the expiration of this Warrant, then, as a part of such reorganization, recapitalization, merger or consolidation, lawful provision shall be made so that the Holder shall thereafter be entitled to receive upon exercise of his rights to purchase the
Shares hereunder, the kind and amount of securities, cash or other property of the successor corporation resulting from such reorganization, recapitalization, merger or consolidation, 

  

 6. 

 
equivalent in value to that which a holder of the Common Stock deliverable upon exercise of such rights to purchase the Shares hereunder would have been
entitled in such reorganization, recapitalization, merger or consolidation if such rights to purchase the Shares hereunder had been exercised immediately prior to such reorganization, recapitalization, merger or consolidation. In any such case,
appropriate adjustment (as determined in good faith by the Company’s Board of Directors) shall be made in the application of the provisions of this Warrant with respect to the rights and interests of the Holder after such reorganization,
recapitalization, merger or consolidation to the end that the provisions of this Warrant (including adjustments of the applicable exercise price(s) and number of shares of Common Stock purchasable pursuant to the terms and conditions of this
Warrant) shall be applicable after the event, as near as reasonably may be, in relation to any shares or other securities deliverable after that event upon the exercise of the Holder’s rights to purchase the Shares pursuant to this Warrant.

  
 (b) Reclassification of Shares. If the Company at any
time after the date hereof shall, by combination, reclassification, exchange, capital reorganization or subdivision of securities or otherwise (other than a combination, reclassification, exchange, capital reorganization or subdivision of securities
or a related reorganization, recapitalization, merger, consolidation or other transaction otherwise provided for herein), change any of the securities as to which purchase rights under this Warrant exist into the same or a different number of
securities of any other class or classes, this Warrant shall thereafter provide for the right or rights to acquire such number and kind of securities as would have been issuable as the result of such change with respect to the securities which were
subject to the purchase rights under this Warrant immediately prior to such combination, reclassification, exchange, capital reorganization, subdivision or other change. In any such case, appropriate adjustment (as determined in good faith by the
Company’s Board of Directors) shall be made in the application of the provisions of this Warrant with respect to the rights and interests of the Holder after such combination, reclassification, capital reorganization, exchange, subdivision or
change to the end that the provisions of this Warrant (including adjustments of the applicable exercise price(s) and number of shares of Common Stock purchasable pursuant to the terms and conditions of this Warrant) shall be applicable after the
event, as near as reasonably may be, in relation to any shares or other securities deliverable after that event upon the exercise of the Holder’s rights to purchase the Shares pursuant to this Warrant. 
  
 (c) Subdivisions and Combinations. In the event that the Company
shall at any time subdivide (by stock split, by payment of a stock dividend or otherwise) the outstanding shares of Common Stock, the number of Shares issuable upon exercise of the rights under this Warrant immediately prior to such subdivision
shall, concurrently with the effectiveness of such subdivision, be proportionately increased, and the applicable exercise price(s) shall be proportionately decreased, and in the event that the Company shall at any time combine (by reclassification
or otherwise) the outstanding shares of Common Stock into a lesser number of shares of Common Stock, the number of Shares issuable upon exercise of the rights under this Warrant immediately prior to such combination shall, concurrently with the
effectiveness of such combination, be proportionately decreased, and the applicable exercise price(s) shall be proportionately increased. 
  
 (d) Notice of Adjustments. Upon any adjustment of any of the exercise prices or any increase or decrease in the number of Shares purchasable upon
the exercise of the rights under this Warrant in accordance with this Section 9, then, and in each such case, the Company, within thirty (30) days thereafter, shall promptly give notice thereof, to the Holder at the address of such Holder as shown
on the Warrant Register of the Company, delivered by any method provided in Section 11(d) hereof, which notice shall state the event giving rise to the 

  

 7. 

 
adjustment, the exercise price(s) as adjusted and, if applicable, the increased or decreased number of Shares purchasable upon the exercise of the rights
under this Warrant, setting forth in reasonable detail the method of calculation of each. 
  
 (e) Other Notices. In the event that the Company shall authorize: (1) the issuance of any dividend or other distribution on the Common Stock (other than: (i) repurchases of Common Stock issued to or held by
employees, officers, directors or consultants of the Company or its subsidiaries upon termination of their employment or services pursuant to agreements providing for the right of said repurchase; (ii) repurchases of Common Stock issued to or held
by employees, officers, directors or consultants of the Company or its subsidiaries pursuant to rights of first refusal contained in agreements providing for such right; or (iii) repurchases of capital stock of the Company in connection with the
settlement of disputes with any stockholder), whether in cash, property, stock or other securities; (2) the voluntary liquidation, dissolution or winding up of the Company; or (3) any transaction resulting in the expiration of this Warrant; then, in
each such case, the Company shall give written notice thereof to the Holder at the address of such Holder as shown on the Warrant Register of the Company, delivered by any method provided in Section 11(d) hereof, at least five (5) days prior to the
effective date of such event. The notice provisions set forth in this section may be shortened or waived prospectively or retrospectively by the vote or written consent of the holders of a majority of the Shares issuable upon exercise of the rights
under this Warrant. 
  
 10. No Rights as Stockholder.
Nothing contained herein shall entitle the Holder to any rights as a stockholder of the Company or to be deemed the holder of Common Stock or any other securities that may at any time be issuable on the exercise of the rights hereunder for any
purpose nor shall anything contained herein be construed to confer upon the Holder, as such, any right to vote for the election of directors or upon any matter submitted to stockholders at any meeting thereof, or to give or withhold consent to any
corporate action (whether upon any recapitalization, issuance of stock, reclassification of stock, change of par value or change of stock to no par value, consolidation, merger, conveyance or otherwise) or to receive notice of meetings, or to
receive dividends or subscription rights or otherwise or any other rights of a stockholder of the Company until the rights under the Warrant shall have been exercised and the Shares purchasable upon exercise of the rights hereunder shall have become
deliverable as provided herein. 
  
 11. Miscellaneous.

  
 (a) Effective Date. The provisions of this Warrant
shall be construed and shall be given effect in all respects as if it had been executed and delivered by the Company on the date hereof. 
  
 (b) Waiver and Amendment. Any provision of this Warrant may be amended, waived or modified only upon the written consent of the Company and the
Holder. 
  
 (c) Successors and Assigns. Except as provided
in Section 6, this Warrant, and any and all rights, duties and obligations hereunder, shall not be assigned, transferred, delegated or sublicensed by any party hereto without the prior written consent of the other party. Any attempt by a party
without such permission to assign, transfer, delegate or sublicense any rights, duties or obligations that arise under this Warrant shall be void. Subject to the foregoing and except as otherwise provided herein, the provisions of this Warrant shall
inure to the benefit of, and be binding upon, the successors and assigns of the parties. 
  

 8. 

 (d) Notices. All notices and other communications provided for hereunder shall be in writing and
delivered, mailed or telecopied. Notices and other communications to the Holder shall be directed to the Holder at his address as shown on the Warrant Register maintained by the Company; and notices and other communications to the Company shall be
directed to the Company at its address as shown on the signature page hereto (any notice or other communication sent to the Company should be directed to the attention of the President or Chief Financial Officer of the Company); or, as to each
party, at such other address as shall be designated by such party in a written notice to the other party pursuant hereto. Any such notice or other communication shall be deemed to have been duly given (i) when sent by Federal Express or other
overnight delivery service of recognized standing, on the business day following deposit with such service; (ii) when mailed by registered or certified mail, first class postage prepaid and addressed as aforesaid through the United States Postal
Service, upon receipt; (iii) when delivered by hand, upon delivery; and (iv) when telecopied, upon confirmation of receipt. Any party hereto may by notice so given change its address for future notice hereunder. 
  
 (e) Governing Law. This Warrant and all actions arising out of or in
connection with this Warrant shall be governed by and construed in accordance with the laws of the State of Delaware, without regard to the conflicts of law provisions of the State of Delaware, or of any other state. 
  
 (f) Further Assurances. Each party hereto agrees to execute and
deliver, by the proper exercise of its corporate, limited liability company, partnership or other powers, all such other and additional instruments and documents and do all such other acts and things as may be reasonably necessary to more fully
effectuate this Warrant. 
  
 (g) Entire Agreement. Except
as expressly set forth herein, this Warrant (including the exhibits attached hereto) constitutes the entire agreement and understanding of the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and
understandings relating to such subject matter. 
  
 (h) WAIVER
OF JURY TRIAL. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY AND ANY ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS WARRANT OR THE ACTIONS OF
ANY PARTY HERETO IN NEGOTIATION, ADMINISTRATION, PERFORMANCE OR ENFORCEMENT HEREOF. 
  
 (i) Counterparts. This Warrant may be executed in one or more counterparts, all of which shall be considered one and the same agreement and shall become effective when one or more counterparts have been signed
by each of the parties and delivered to the other party, it being understood that all parties need not sign the same counterpart. 
  
 (j) Titles and Subtitles. The titles and subtitles used in this Warrant are used for convenience only and are not to be considered in construing or
interpreting this Warrant. All references in this Warrant to sections, paragraphs and exhibits shall, unless otherwise provided, refer to sections and paragraphs hereof and exhibits attached hereto. 
  

 9. 

 IN WITNESS WHEREOF, the Company has caused this Warrant to be executed as of the date first above
written. 
  

	HEALTHETECH, INC.
		
	 By:
	 	 /s/    DeWayne R.
Youngberg        

	 	 	 DeWayne R. Youngberg

	 	 	 Vice President & General Counsel

			
	 	 	 Address:
	 	     523 Park Point Drive, 3rd Floor

	 	 	 	 	     Golden, Colorado 80401

  
 In connection with the execution
of this Warrant, the undersigned Holder acknowledges and agrees to the Representations and Warranties of the Holder contained in Section 5 hereof: 
  

	 By:
	 	 /s/    Norbert
Sieber        

	 	 	 Name:
	 	 Norbert Sieber

	 	 	 Title:
	 	 Executive Vice President

		
	 	 	 Address:

  
 (Signature
Page to Warrant to Purchase Shares of Common Stock of HealtheTech, Inc.) 

 EXHIBIT A 
  
 NOTICE OF EXERCISE 
  
 TO:             HEALTHETECH, INC. 
  
 ATTN:       PRESIDENT 
  
 (1) The undersigned Holder hereby elects to purchase
             shares of the Common Stock of HEALTHETECH, INC., pursuant to the terms of the attached Warrant to Purchase Shares of Common Stock, dated as of August 28, 2003 (the
“Warrant”), between HEALTHETECH, INC. and the Holder, and tenders herewith payment of the purchase price for such shares in full, together with all applicable transfer taxes, if any. 
  
 (2) Please issue a certificate or certificates representing said shares of
Common Stock in the name of the undersigned or in such other name as is specified below: 
  

	  

	 Name

	  

	 Address

  
 (3) Please issue
a new Warrant for the unexercised portion of the attached Warrant in the name of the undersigned or in such other name as is specified below: 
  

	  

	 Name

	  

	 Address

  
 (4) The
undersigned hereby represents and warrants that the aforesaid shares of Common Stock are being acquired for investment, solely for the account of the undersigned and not as a nominee for any other person and not with a view to, or for resale in
connection with, the distribution thereof, and that the undersigned has no present intention of distributing or reselling such shares except under circumstances that will not result in a violation of the Securities Act of 1933, as amended, or any
applicable state securities laws, and all representations and warranties of the undersigned set forth in Section 5 and Section 6(e) of the attached Warrant are true and correct as of the date hereof. In support thereof, the undersigned
agrees to execute an Investment Representation Statement in a form substantially similar to the form attached to the Warrant as Exhibit C. 
  

	  

	  	  

	 Date
	  	 Signature

	 	  	  

	 	  	 Name

	 	  	  

	 	  	Title and Name of Entity (if signing on
behalf of an entity)

 EXHIBIT B 
  
 ASSIGNMENT FORM 
  

	ASSIGNOR:	                                     
    

	COMPANY:	HEALTHETECH, INC. 

	WARRANT:	THE WARRANT (THE “WARRANT”) TO PURCHASE SHARES OF COMMON STOCK ISSUED ON AUGUST 28, 2003 (THE “WARRANT”) 

	DATE:	                ,
             

  
 FOR VALUE RECEIVED, the undersigned registered Holder of the Warrant (“Assignor”) hereby sells, assigns and transfers unto the Assignee named below all of the rights of the undersigned under the
within Warrant, with respect to the number of shares of Common Stock set forth below: 
  

	 Name of Assignee

	  	 Address

	  	 Number of Shares

	  	 Exercise Period

	 	  	 	  	 	  	 
	 	  	 	  	 	  	 

  
 and does irrevocably constitute and
appoint                      as attorney to make such transfer on the books of HEALTHETECH, INC., maintained for the purpose, with full power
of substitution in the premises. 
  
 Each of the Assignor and
Assignee also represent and warrant that, by assignment hereof, the Assignee acknowledges that the Warrant and the shares of stock to be issued upon exercise of the rights thereunder are being acquired for investment and that the Assignee will not
offer, sell or otherwise dispose of the Warrant or any shares of stock to be issued upon exercise of the rights thereunder except under circumstances which will not result in a violation of the Securities Act of 1933, as amended, or any state
securities laws. Further, the Assignee has acknowledged that upon exercise of any rights under the Warrant, the Assignee shall, if requested by the Company, confirm in writing, in a form satisfactory to the Company, that the shares of stock so
purchased are being acquired for investment and not with a view toward distribution or resale. In support thereof, the undersigned Assignee agrees to execute an Investment Representation Statement in a form substantially similar to the form attached
to the Warrant as Exhibit C in connection with this assignment and any exercise of the rights under the Warrant. 
  

	ASSIGNOR:	 	 	 	ASSIGNEE:	 	 
				
	 By:
	 	  

	 	 By:
	 	  

	 	 	 Name:
	 	 	 	 Name:

	 	 	 Title:
	 	 	 	 Title:

						
	 	 	 Address:
	 	  

	 	 	 	 Address:
	 	  

	 	 	  

	 	 	 	  

 EXHIBIT C 
  
 INVESTMENT REPRESENTATION STATEMENT 
  

	HOLDER:	                                      
   

	COMPANY:	HEALTHETECH, INC. 

	SECURITIES:	THE WARRANT (THE “WARRANT”) TO PURCHASE SHARES OF COMMON STOCK ISSUED ONAUGUST 28, 2003 AND THE COMMON STOCK ISSUED OR ISSUABLE UPON EXERCISE THEREOF

  

	AMOUNT:	                     SHARES 

  

	DATE:	                ,              

  
 In connection with the purchase of the above-listed Securities, the
undersigned Holder represents and warrants to, and agrees with, the Company as follows: 
  
 1. Investment Intent. The Holder is acquiring the Securities for investment for his own account, not as a nominee or agent, and not with the view to, or for resale in connection with, any distribution thereof.

  
 2. Investment Experience. The Holder has substantial
experience in evaluating and investing in private placement transactions of securities in companies similar to the Company so that he is capable of evaluating the merits and risks of his investment in the Company and has the capacity to protect his
own interests. 
  
 3. Speculative Nature of Investment. The
Holder acknowledges that his investment in the Company is highly speculative and entails a substantial degree of risk and the Holder is in a position to lose the entire amount of such investment. 
  
 4. Access to Data. The Holder has had an opportunity to discuss the
Company’s business, management and financial affairs with the Company’s management. The Holder has also had an opportunity to ask questions of officers of the Company, which questions were answered to its satisfaction. The Holder
understands that such discussions, as well as any information issued by the Company, were intended to describe certain aspects of the Company’s business and prospects, but were not necessarily a thorough or exhaustive description. The Holder
acknowledges that any business plans prepared by the Company have been, and continue to be, subject to change and that any projections included in such business plans or otherwise are necessarily speculative in nature, and he can be expected that
some or all of the assumptions underlying the projections will not materialize or will vary significantly from actual results. 
  
 5. Accredited Investor. The Holder is an “accredited investor” within the meaning of Regulation D, Rule 501(a), promulgated by the
Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”). 
  
 6. Residency. The residency of the Holder (or, in the case of a partnership or corporation, such entity’s principal place of business) is
correctly set forth on the signature page hereto. 
  

 Exhibit C – Page 1. 

 7. Restriction on Resales. The Holder acknowledges that the Securities must be held indefinitely
unless subsequently registered under the Securities Act or unless an exemption from such registration is available. The Holder further understands that there is no assurance that any exemption from registration under the Securities Act will be
available or, if available, that such exemption will allow the Holder to dispose of or otherwise transfer any or all of the Securities under the circumstances, in the amounts or at the times the Holder might propose. 
  
 8. Rule 144. The Holder is aware of the provisions of Rule 144
promulgated under the Securities Act which permit limited resale of shares purchased in a private placement subject to the satisfaction of certain conditions, including among other things, the existence of a public market for the shares, the
availability of certain current public information about the Company, the resale occurring not less than one year after a party has purchased and paid for the security to be sold, the sale being effected through a “broker’s
transaction” or in transactions directly with a “market maker” and the number of shares being sold during any three-month period not exceeding specified limitations. The Holder acknowledges that, in the event all of the requirements
of Rule 144 are not met, registration under the Securities Act or an exemption from registration will be required for any disposition of the Securities. The Holder understands that, although Rule 144 is not exclusive, the Securities and Exchange
Commission has expressed its opinion that persons proposing to sell restricted securities received in a private offering other than in a registered offering or pursuant to Rule 144 will have a substantial burden of proof in establishing that an
exemption from registration is available for such offers or sales and that such persons and the brokers who participate in the transactions do so at their own risk. 
  
 9. Authorization. The Holder has all requisite power and authority to execute and deliver the Warrant, to purchase
the Securities and to carry out and perform its obligations under the terms of the Warrant. All action on the part of the Holder necessary for the authorization, execution, delivery and performance of the Warrant, and the performance of all of the
Holder’s obligations under the Warrant, has been taken or will be taken prior to the purchase of the Warrant. 
  
 (b) The Warrant, when executed and delivered by the Holder, will constitute a valid and legally binding obligation of the Holder, enforceable in
accordance with its terms except: (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, and (ii) as limited by laws relating
to the availability of specific performance, injunctive relief or other equitable remedies or by general principles of equity. 
  
 (c) No consent, approval, authorization, order, filing, registration or qualification of or with any court, governmental authority or third person is
required to be obtained by the Holder in connection with the execution and delivery of the Warrant or the performance of the Holder’s obligations hereunder. 
  
 10. Brokers or Finders. The Holder has not engaged any brokers, finders or agents, and the Company has not incurred
and will not incur, directly or indirectly, as a result of any action taken by the Holder, any liability for brokerage or finders’ fees or agents’ commissions or any similar charges in connection with the Warrant. 
  
 11. Investor Counsel. The Holder acknowledges that he has had the
opportunity to review the Warrant and the exhibits attached thereto and the transactions contemplated by the Warrant with his own legal counsel. The Holder is relying solely on such counsel and not on any statements or representations of the Company
or its agents for legal advice with respect to this investment or the transactions contemplated by the Warrant. 
  

 Exhibit C – Page 2. 

 12. Tax Advisors. The Holder has reviewed with his own tax advisors the U.S. federal, state, local
and foreign tax consequences of this investment and the transactions contemplated by the Warrant. With respect to such matters, the Holder relies solely on such advisors and not on any statements or representations of the Company or any of its
agents, written or oral. The Holder understands that it (and not the Company) shall be responsible for his own tax liability that may arise as a result of this investment or the transactions contemplated by the Warrant. 
  
 13. Further Limitations on Disposition. Without in any way limiting
the representations and warranties set forth above, the Holder agrees not to make any disposition of all or any portion of the Securities unless and until, and it shall be a condition to the transfer of all or any portion of the Securities that: (1)
there is then in effect a registration statement under the Securities Act covering such proposed disposition and such disposition is made in accordance with such registration statement or (2) (A) the Holder shall have notified the Company of the
proposed disposition and shall have furnished the Company with a detailed statement of the circumstances surrounding the proposed disposition, (B) the transferee shall have agreed in writing to be bound by and subject to the terms, conditions,
restrictions, obligations and other limitations set forth in the Warrant to the same extent as if such transferee were the original Holder thereunder, (C) the transferee shall have confirmed to the satisfaction of the Company in writing,
substantially in the form attached to the Warrant as Exhibit C, that the Securities are being acquired solely for the transferee’s own account and not as a nominee for any other party, for investment and not with a view toward
distribution or resale and that the transferee shall have confirmed such other matters related thereto as may be reasonably requested by the Company, and (D) if requested by the Company, the Holder shall have furnished the Company with an opinion of
counsel, reasonably satisfactory to the Company, that such disposition will not require registration of the Securities under the Securities Act. The Securities that are transferred to a transferee shall be subject to the terms, conditions,
restrictions, obligations and other limitations set forth herein and therein. 
  
 (The remainder of this page is intentionally left blank.) 
  

 Exhibit C – Page 3. 

 IN WITNESS WHEREOF, the Holder has caused this Investment Representation Statement to be duly executed
and delivered by its proper and duly authorized officers as of the date and year first written above. 
  

	HOLDER:	 	 
		
	 By:
	 	  

	 Name:
	 	  

	 Title:
	 	  

	 Address:
	 	 
	  

	  

	  

  
 (Signature
page to the Investment Representation Statement)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00057-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00057-of-00352.parquet"}]]